| 177Lu-edotreotide | drug | no external link or Wikipedia reference |
| 18F-MFBG PET replacing 123I-MIBG scintigraphy | idea | no external link or Wikipedia reference |
| A $50 million prize for the first off-patent drug proven to extend cancer survival | idea | no external link or Wikipedia reference |
| A 28-day national pathway for people with a positive multi-cancer blood test | idea | no external link or Wikipedia reference |
| A biomarker-directed trial of vitamin D after surgery for digestive tract cancers | idea | no external link or Wikipedia reference |
| A blood test for the pre-metastatic niche | idea | no external link or Wikipedia reference |
| A bone drug to prevent breast cancer in BRCA1 carriers | idea | no external link or Wikipedia reference |
| A bone marrow niche on a chip to study human dormancy | idea | no external link or Wikipedia reference |
| A breath test to rule out cancer in people with vague symptoms | idea | no external link or Wikipedia reference |
| A cancer blood test for older people arriving at A&E with unexplained symptoms | idea | no external link or Wikipedia reference |
| A chatbot for pre-test genetic counselling so counsellors see only who needs them | idea | no external link or Wikipedia reference |
| A cheap old tablet to restore appetite | idea | no external link or Wikipedia reference |
| A clone report from blood at every treatment cycle | idea | no external link or Wikipedia reference |
| A consented commons of surgical video linked to pathology and outcomes | idea | no external link or Wikipedia reference |
| A dedicated clinic for people whose blood test says the cancer is back | idea | no external link or Wikipedia reference |
| A dedicated global financing window for cancer, modelled on the Global Fund | idea | no external link or Wikipedia reference |
| A dedicated programme for cachexia and treatment toxicity research | idea | no external link or Wikipedia reference |
| A defined pathway for patients with both dementia and cancer | idea | no external link or Wikipedia reference |
| A delinked market-entry reward paid by payers when a repurposed generic wins approval | idea | no external link or Wikipedia reference |
| A dietitian in every gastrointestinal and head and neck tumour board | idea | no external link or Wikipedia reference |
| A digital second-opinion network answering community oncologists within 72 hours | idea | no external link or Wikipedia reference |
| A diversified royalty pool that finances academic phase 1 trials across fifty assets | idea | no external link or Wikipedia reference |
| A dose-finding trial for exercise after cancer | idea | no external link or Wikipedia reference |
| A drug screen that only rewards killing sleeping cancer cells | idea | no external link or Wikipedia reference |
| A DRUP-style protocol for off-label generic targeted drugs in rare tumours | idea | no external link or Wikipedia reference |
| A federated learning consortium of cancer centres that jointly own the models | idea | no external link or Wikipedia reference |
| A fixed share of trial-group funding for getting proven care to patients | idea | no external link or Wikipedia reference |
| A formal regulatory route for validating a biomarker on archived trial samples | idea | no external link or Wikipedia reference |
| A frameshift neoantigen vaccine for Lynch syndrome carriers as the first preventive cancer vaccine approval | idea | no external link or Wikipedia reference |
| A functional test for homologous recombination deficiency validated across laboratories | idea | no external link or Wikipedia reference |
| A fund for prospective validation of academic biomarkers and companion diagnostics | idea | no external link or Wikipedia reference |
| A funded expert second opinion for every new high-stakes or rare cancer diagnosis | idea | no external link or Wikipedia reference |
| A funded programme of organ-preservation trials to avoid radical surgery | idea | no external link or Wikipedia reference |
| A funder-backed, indexed journal of negative and inconclusive cancer results | idea | no external link or Wikipedia reference |
| A global federated real-world evidence network at regulatory grade | idea | no external link or Wikipedia reference |
| A global first-in-human network for academic cancer trials with single ethics review | idea | no external link or Wikipedia reference |
| A global ledger of negative results and failed compounds with mandatory deposition | idea | no external link or Wikipedia reference |
| A global medical isotope supply observatory with forecasts and shortage alerts | idea | no external link or Wikipedia reference |
| A guaranteed purchase prize for the first drug against a named hard target | idea | no external link or Wikipedia reference |
| A guideline fast track for repurposed drugs with phase 3 evidence but no manufacturer | idea | no external link or Wikipedia reference |
| A health-literacy certification standard for oncology portals, letters and apps | idea | no external link or Wikipedia reference |
| A home for the animal and organoid experiments that failed | idea | no external link or Wikipedia reference |
| A joint price negotiation bloc for middle-income countries, modelled on Beneluxa | idea | no external link or Wikipedia reference |
| A liability framework for clinical AI: safe harbour for clinicians, liability for makers | idea | no external link or Wikipedia reference |
| A lifelong late-effects registry linked to every treatment for adult survivors | idea | no external link or Wikipedia reference |
| A live 'seats available' feed for trial slots, like airline inventory | idea | no external link or Wikipedia reference |
| A live national dashboard of stage at diagnosis as the scorecard for early detection | idea | no external link or Wikipedia reference |
| A live stock-out map for essential chemotherapy drugs | idea | no external link or Wikipedia reference |
| A machine-readable taxonomy of why cancer drugs fail | idea | no external link or Wikipedia reference |
| A machine-readable treatment summary handed to every patient and readable by any hospital | idea | no external link or Wikipedia reference |
| A mandatory decision aid before any multi-cancer blood test | idea | no external link or Wikipedia reference |
| A mandatory silent (shadow) trial before any cancer AI goes live | idea | no external link or Wikipedia reference |
| A mandatory trial line in every tumour board recommendation | idea | no external link or Wikipedia reference |
| A monthly-updated benchmark for AI answers to oncology questions with citation accuracy | idea | no external link or Wikipedia reference |
| A national late-effects registry linking treatment exposures to outcomes decades later | idea | no external link or Wikipedia reference |
| A national non-profit contract research organisation for academic oncology trials | idea | no external link or Wikipedia reference |
| A national platform trial that every ctDNA-positive patient can join | idea | no external link or Wikipedia reference |
| A national repository of radiotherapy dose plans linked to outcomes | idea | no external link or Wikipedia reference |
| A national residual-disease weather service: serial blood tests for every curatively treated patient, pooled | idea | no external link or Wikipedia reference |
| A neutral platform trial for radiotherapy plus immunotherapy combinations | idea | no external link or Wikipedia reference |
| A neutral public evaluator for cancer AI, on the model of NIST | idea | no external link or Wikipedia reference |
| A neutral slot exchange so unused CAR-T manufacturing slots go to the next patient | idea | no external link or Wikipedia reference |
| A non-profit company to hold marketing authorisations for repurposed cancer drugs | idea | no external link or Wikipedia reference |
| A non-profit phase 1b combination unit that any drug owner can use | idea | no external link or Wikipedia reference |
| A paediatric palliative care team in every childhood cancer unit | idea | no external link or Wikipedia reference |
| A paid patient navigator for every new cancer diagnosis, reimbursed as a service | idea | no external link or Wikipedia reference |
| A patent pool for combination method-of-use claims | idea | no external link or Wikipedia reference |
| A permanent platform trial for supportive-care interventions inside cooperative groups | idea | no external link or Wikipedia reference |
| A phase 0 fund to test academic compounds in humans with microdoses and imaging | idea | no external link or Wikipedia reference |
| A plain-language explainer for every guideline recommendation, in every major language | idea | no external link or Wikipedia reference |
| A platform trial of very-low-cost metronomic chemotherapy in LMIC common cancers | idea | no external link or Wikipedia reference |
| A pragmatic trial network for intraoperative margin tools, paid on margin reduction | idea | no external link or Wikipedia reference |
| A pragmatic trial of statins to prevent liver cancer in people with cirrhosis | idea | no external link or Wikipedia reference |
| A pre-competitive consortium to train a shared multimodal cancer foundation model | idea | no external link or Wikipedia reference |
| A prevention programme for chemotherapy nerve damage: SARM1 inhibitors, cooling and compression | idea | no external link or Wikipedia reference |
| A public API serving the current standard of care for any cancer, stage and biomarker | idea | no external link or Wikipedia reference |
| A public benchmark and audit of chatbot answers to cancer questions | idea | no external link or Wikipedia reference |
| A public biomarker validation utility with pre-diagnostic biobanks and blinded testing | idea | no external link or Wikipedia reference |
| A public equity index for trial sites and sponsors, tied to funding | idea | no external link or Wikipedia reference |
| A public fund and label pathway to trial generic drugs against cancer | idea | no external link or Wikipedia reference |
| A public indemnity pool so universities can sponsor first-in-human cancer trials | idea | no external link or Wikipedia reference |
| A public index of how the same cancer drug's label differs between countries | idea | no external link or Wikipedia reference |
| A public map of trial deserts to steer where new sites open | idea | no external link or Wikipedia reference |
| A public registry of cancer treatments that were later shown not to work | idea | no external link or Wikipedia reference |
| A public registry of unproven cancer clinics and reported outcomes | idea | no external link or Wikipedia reference |
| A public tracker of how long each country takes to adopt new evidence | idea | no external link or Wikipedia reference |
| A public-benefit phase 1 factory that takes academic discoveries into first-in-human trials | idea | no external link or Wikipedia reference |
| A randomised trial of a shared-antigen vaccine to prevent Lynch syndrome cancers | idea | no external link or Wikipedia reference |
| A randomised trial of AI scribes in oncology clinics measuring errors and time | idea | no external link or Wikipedia reference |
| A randomised trial of AI-generated treatment recommendations versus tumour boards | idea | no external link or Wikipedia reference |
| A real-world sequencing analysis within a year of every new approval | idea | no external link or Wikipedia reference |
| A registry for preclinical experiments that did not work | idea | no external link or Wikipedia reference |
| A registry of every treatment sequence patients actually receive, with outcomes | idea | no external link or Wikipedia reference |
| A registry of external validation datasets for cancer AI models, with mandatory reporting | idea | no external link or Wikipedia reference |
| A reliance pathway for companion diagnostics so the test arrives with the drug | idea | no external link or Wikipedia reference |
| A repurposing label pathway with short exclusivity that non-profits can hold | idea | no external link or Wikipedia reference |
| A risk-stratified cardio-oncology pathway for everyone receiving heart-toxic cancer therapy | idea | no external link or Wikipedia reference |
| A same-week expert second opinion for every rare cancer diagnosis | idea | no external link or Wikipedia reference |
| A shared AI review assistant that maps one dossier to every regulator's questions | idea | no external link or Wikipedia reference |
| A shared compound library that rare cancer researchers can actually use | idea | no external link or Wikipedia reference |
| A short pre-surgery drug window as the default early test of new agents | idea | no external link or Wikipedia reference |
| A single 'cancer check at 60' appointment bundling all screening tests | idea | no external link or Wikipedia reference |
| A skull ultrasound implant that opens the barrier at every cycle | idea | no external link or Wikipedia reference |
| A social impact bond: investors fund a repurposing trial, payers repay from savings | idea | no external link or Wikipedia reference |
| A standard evaluation pathway for AI-assisted pathology, from reader study to deployment | idea | no external link or Wikipedia reference |
| A standard evolvability score for every tumour | idea | no external link or Wikipedia reference |
| A standard for monitoring AI performance drift with pause thresholds | idea | no external link or Wikipedia reference |
| A standard for tumour-agnostic approvals: minimum histologies and hierarchical modelling | idea | no external link or Wikipedia reference |
| A standard handoff with medication reconciliation at every cancer care transition | idea | no external link or Wikipedia reference |
| A standard platform to get drugs into the brain: focused ultrasound plus shuttle-engineered therapeutics | idea | no external link or Wikipedia reference |
| A standing platform trial that assigns treatment by how the tumour escaped | idea | no external link or Wikipedia reference |
| A statutory minimum share of public trial money for surgery and radiotherapy | idea | no external link or Wikipedia reference |
| A strategic reserve of essential generic cancer drugs to end recurring shortages | idea | no external link or Wikipedia reference |
| A structured pathway for patients declining proven treatment | idea | no external link or Wikipedia reference |
| A survivor biobank to find who will develop late effects before they do | idea | no external link or Wikipedia reference |
| A survivorship passport app for adolescent and young adult survivors | idea | no external link or Wikipedia reference |
| A survivorship research endowment funded by a levy on curative therapy prices | idea | no external link or Wikipedia reference |
| A swallowable sponge test for reflux patients, offered in pharmacies | idea | no external link or Wikipedia reference |
| A ten-dollar blood test for the five cancers that kill most people in poorer countries | idea | no external link or Wikipedia reference |
| A ten-year cohort of incidental findings to calibrate follow-up guidelines | idea | no external link or Wikipedia reference |
| A test to tell true oligometastatic disease from hidden widespread spread | idea | no external link or Wikipedia reference |
| A therapeutic vaccine to clear cervical precancer without surgery | idea | no external link or Wikipedia reference |
| A translation fund for academic surgical devices and radiotherapy technology | idea | no external link or Wikipedia reference |
| A trial of GLP-1 weight-loss drugs with cancer as the primary outcome | idea | no external link or Wikipedia reference |
| A trials fund reserved for older and multimorbid patients | idea | no external link or Wikipedia reference |
| A tumour board assistant that cites its evidence and tracks outcomes | idea | no external link or Wikipedia reference |
| A university cyclotron network with shared regulatory files for new tracers | idea | no external link or Wikipedia reference |
| A urine DNA test to decide who with blood in the urine needs a camera test | idea | no external link or Wikipedia reference |
| A vaccine against H. pylori for children in high-risk regions | idea | no external link or Wikipedia reference |
| A video-based surgical quality registry linking assessed skill to cancer outcomes | idea | no external link or Wikipedia reference |
| A virtual cancer cell that predicts what a drug will do before you test it | idea | no external link or Wikipedia reference |
| A watch-and-wait registry for blood precursor conditions found by chance | idea | no external link or Wikipedia reference |
| A whole-population cancer interception programme: risk-stratify every adult, detect and intercept early | idea | no external link or Wikipedia reference |
| A. Keith Stewart | person | no external link or Wikipedia reference |
| Aaron D. Schimmer | person | no external link or Wikipedia reference |
| Acid-labile hydrazone (AcBut) | term | no external link or Wikipedia reference |
| Actinium-225 DOTATATE | drug | no external link or Wikipedia reference |
| Actinium-225 PSMA agents | drug | no external link or Wikipedia reference |
| Active surveillance as the default for tiny papillary thyroid cancers | idea | no external link or Wikipedia reference |
| Active surveillance of papillary microcarcinoma | technology | no external link or Wikipedia reference |
| Acute oncology assessment units so sick cancer patients bypass the emergency department | idea | no external link or Wikipedia reference |
| ADC + checkpoint inhibitor | pairing | no external link or Wikipedia reference |
| ADC bioconjugation manufacturing (CDMOs) | technology | no external link or Wikipedia reference |
| ADC for residual disease after KEYNOTE-522 | idea | no external link or Wikipedia reference |
| ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs | roadmap | no external link or Wikipedia reference |
| ADC sequencing | term | no external link or Wikipedia reference |
| Add a cheap-drug factorial arm to every cooperative-group adjuvant cancer trial | idea | no external link or Wikipedia reference |
| Add a drug when the blood test turns, without stopping the one that works | idea | no external link or Wikipedia reference |
| Add the second drug on day one when the escape route is predictable | idea | no external link or Wikipedia reference |
| Adopt tumour-agnostic cancer drug labels across regions by reliance, not re-review | idea | no external link or Wikipedia reference |
| Adrian R. Krainer | person | no external link or Wikipedia reference |
| Advanced-practice radiation therapists doing contouring and on-treatment reviews | idea | no external link or Wikipedia reference |
| After the COMET trial: surveillance pathways and a new name for low-risk DCIS | idea | no external link or Wikipedia reference |
| Aggregated single-patient crossover trials for symptom and supportive treatments | idea | no external link or Wikipedia reference |
| Agree in advance how to borrow evidence between similar rare cancers | idea | no external link or Wikipedia reference |
| AI & Computation | section | no external link or Wikipedia reference |
| AI auto-contouring and adaptive planning | technology | no external link or Wikipedia reference |
| AI clears the normal lung screening scans so radiologists read only the suspicious ones | idea | no external link or Wikipedia reference |
| AI compute and model platforms for oncology | technology | no external link or Wikipedia reference |
| AI in the oncology clinic: from narrow cleared tools to multimodal decision support | roadmap | no external link or Wikipedia reference |
| AI malignancy scores to end repeat scans and biopsies for benign lung nodules | idea | no external link or Wikipedia reference |
| AI pathology → androgen deprivation duration | pairing | no external link or Wikipedia reference |
| AI quantification of HER2-low and HER2-ultralow | idea | no external link or Wikipedia reference |
| AI second reads to stop borderline lesions being upgraded to cancer | idea | no external link or Wikipedia reference |
| AI that spots pancreatic cancer on scans taken a year before diagnosis | idea | no external link or Wikipedia reference |
| AI trial matching & clinical decision support | technology | no external link or Wikipedia reference |
| AI-assisted central imaging reads to cut endpoint cost and variability | idea | no external link or Wikipedia reference |
| AI-designed proteins that grip the floppy parts of cancer drivers | idea | no external link or Wikipedia reference |
| AI-first reading for high-volume common cancer diagnoses, pathologist for the exceptions | idea | no external link or Wikipedia reference |
| AK146D1 | drug | no external link or Wikipedia reference |
| Alan Ashworth | person | no external link or Wikipedia reference |
| Alan P. Venook | person | no external link or Wikipedia reference |
| Albert C. Koong | person | no external link or Wikipedia reference |
| Alessandro Gronchi | person | no external link or Wikipedia reference |
| Alex F. Herrera | person | no external link or Wikipedia reference |
| Alexander Drilon | person | no external link or Wikipedia reference |
| Alexander Eggermont | person | no external link or Wikipedia reference |
| Algorithm-triggered goals-of-care conversations before crisis | idea | no external link or Wikipedia reference |
| Alice L. Yu | person | no external link or Wikipedia reference |
| Allogeneic (off-the-shelf) cell therapy | technology | no external link or Wikipedia reference |
| Allogeneic donor and iPSC master cell banks | technology | no external link or Wikipedia reference |
| Alpha radioligands after ADC failure | idea | no external link or Wikipedia reference |
| Alpha vs beta emitters | term | no external link or Wikipedia reference |
| Alpha-emitting PSMA therapy at first metastatic diagnosis | idea | no external link or Wikipedia reference |
| Amar U. Kishan | person | no external link or Wikipedia reference |
| Ambient AI note-taking to give oncologists back a day a week | idea | no external link or Wikipedia reference |
| Amit M. Oza | person | no external link or Wikipedia reference |
| Amivantamab + lazertinib (first-line EGFR NSCLC) | pairing | no external link or Wikipedia reference |
| Amod A. Sarnaik | person | no external link or Wikipedia reference |
| An 18-month oncology track for clinical officers and physician associates | idea | no external link or Wikipedia reference |
| An abbreviated approval path for follow-on antibodies within a validated class | idea | no external link or Wikipedia reference |
| An advance market commitment for PD-1 biosimilars for lower-income countries | idea | no external link or Wikipedia reference |
| An antitrust safe harbour for cross-company combination trials and data pooling | idea | no external link or Wikipedia reference |
| An asynchronous expert second opinion for every new advanced-cancer diagnosis | idea | no external link or Wikipedia reference |
| An automated pipeline emulating trials of every common drug against every cancer | idea | no external link or Wikipedia reference |
| An automatic electronic frailty index inside the oncology record | idea | no external link or Wikipedia reference |
| An Epstein-Barr virus vaccine to prevent nasopharyngeal cancer and lymphomas | idea | no external link or Wikipedia reference |
| An independent evaluation unit for surgical robots and AI, paid on evidence | idea | no external link or Wikipedia reference |
| An independent hype index grading cancer press releases and news stories | idea | no external link or Wikipedia reference |
| An independent replication institute that re-tests key preclinical cancer findings before trials | idea | no external link or Wikipedia reference |
| An international body to rename indolent lesions so 'cancer' means something | idea | no external link or Wikipedia reference |
| An international consortium pooling the outcome of every treated child with cancer | idea | no external link or Wikipedia reference |
| An international registry of real (net) cancer drug prices paid by public payers | idea | no external link or Wikipedia reference |
| An open atlas of collateral sensitivity for every approved targeted drug | idea | no external link or Wikipedia reference |
| An open forecasting tournament on which combination trials will succeed | idea | no external link or Wikipedia reference |
| An open global model of cancer workforce supply and demand by country | idea | no external link or Wikipedia reference |
| An open interoperability standard for closed automated cell-processing machines | idea | no external link or Wikipedia reference |
| An open library pairing completed cancer trials with real-world emulations | idea | no external link or Wikipedia reference |
| An open map of which cancer proteins any drug can stick to | idea | no external link or Wikipedia reference |
| An open model bank for the rare tumours nobody has models for | idea | no external link or Wikipedia reference |
| An open organoid bank for cancers too rare to have models | idea | no external link or Wikipedia reference |
| An open supplement-drug interaction checker built into oncology prescribing | idea | no external link or Wikipedia reference |
| An organotropism atlas that predicts where a cancer will spread | idea | no external link or Wikipedia reference |
| Analyse and dose by sex: women get more toxicity from many cancer drugs at the same dose | idea | no external link or Wikipedia reference |
| Ananya Choudhury | person | no external link or Wikipedia reference |
| Anchor a TGF-beta trap in the tumour stroma so it cannot act everywhere | idea | no external link or Wikipedia reference |
| André Ilbawi | person | no external link or Wikipedia reference |
| Andrea Cercek | person | no external link or Wikipedia reference |
| Andreas Trumpp | person | no external link or Wikipedia reference |
| Andreas von Deimling | person | no external link or Wikipedia reference |
| Andrés Cervantes | person | no external link or Wikipedia reference |
| Andrew J. Aguirre | person | no external link or Wikipedia reference |
| Andrew Tutt | person | no external link or Wikipedia reference |
| Andrew Wardley | person | no external link or Wikipedia reference |
| Angela DeMichele | person | no external link or Wikipedia reference |
| Angelika Eggert | person | no external link or Wikipedia reference |
| Anirban Maitra | person | no external link or Wikipedia reference |
| Anitocabtagene autoleucel | drug | no external link or Wikipedia reference |
| Ann H. Partridge | person | no external link or Wikipedia reference |
| Anna Fagotti | person | no external link or Wikipedia reference |
| Anne C. Chiang | person | no external link or Wikipedia reference |
| Anthony Gonçalves | person | no external link or Wikipedia reference |
| Anthony Letai | person | no external link or Wikipedia reference |
| Anti-EGFR antibody + chemotherapy in left-sided RAS/BRAF wild-type mCRC | pairing | no external link or Wikipedia reference |
| Anti-GD2 antibody + irinotecan-temozolomide (chemoimmunotherapy) | pairing | no external link or Wikipedia reference |
| Antibiotic-resistance testing from a stool sample before treating H. pylori | idea | no external link or Wikipedia reference |
| Antibodies that see mutant KRAS and p53 fragments displayed on the cell surface | idea | no external link or Wikipedia reference |
| Antibody manufacturing (CHO bioprocessing) | technology | no external link or Wikipedia reference |
| Antibody-Drug Conjugates | section | no external link or Wikipedia reference |
| Antoni Ribas | person | no external link or Wikipedia reference |
| Apheresis and starting-material collection | technology | no external link or Wikipedia reference |
| Armoured, logic-gated & next-gen CARs | technology | no external link or Wikipedia reference |
| ArteraAI Breast | drug | no external link or Wikipedia reference |
| ArteraAI Prostate | drug | no external link or Wikipedia reference |
| Artur Katz | person | no external link or Wikipedia reference |
| Arul M. Chinnaiyan | person | no external link or Wikipedia reference |
| ARX788 | drug | no external link or Wikipedia reference |
| Ash A. Alizadeh | person | no external link or Wikipedia reference |
| Ask about diet at diagnosis, and prebunk the myths before the internet does | idea | no external link or Wikipedia reference |
| Atirmociclib | drug | no external link or Wikipedia reference |
| Attack extrachromosomal DNA, the engine of oncogene amplification | idea | no external link or Wikipedia reference |
| Attack the backup copy when a tumour has lost the original gene | idea | no external link or Wikipedia reference |
| Audit whether tumour board recommendations were actually carried out | idea | no external link or Wikipedia reference |
| Aurélien Marabelle | person | no external link or Wikipedia reference |
| Autogene cevumeran | drug | no external link or Wikipedia reference |
| Automated combination discovery: patient-sample screens feeding Bayesian platform trials | idea | no external link or Wikipedia reference |
| Automatic germline testing for every cancer type where it changes care | idea | no external link or Wikipedia reference |
| Automatic offer of shelved cancer assets to non-profits after two years | idea | no external link or Wikipedia reference |
| Automatic price cuts when a cancer drug's approved indications and volumes expand | idea | no external link or Wikipedia reference |
| Automatic reciprocity of orphan and rare-paediatric designations between regulators | idea | no external link or Wikipedia reference |
| Autonomous closed-loop adaptive therapy driven by blood tests and evolutionary models | idea | no external link or Wikipedia reference |
| Avutometinib + defactinib | drug | no external link or Wikipedia reference |
| Ban and enforce against paid advertising of unproven cancer treatments | idea | no external link or Wikipedia reference |
| Ban commercial sunbeds | idea | no external link or Wikipedia reference |
| Ban life and disability insurers from using genetic results | idea | no external link or Wikipedia reference |
| Bank yearly blood from cancer survivors so future tests can be validated | idea | no external link or Wikipedia reference |
| Barbara Bradfield | person | no external link or Wikipedia reference |
| Barcode every reagent lot so batch effects can be traced across experiments and labs | idea | no external link or Wikipedia reference |
| Barcode patient-derived tumours to watch which clones win under each drug | idea | no external link or Wikipedia reference |
| Bayesian shrinkage for subgroup claims to stop false 'works in this group' stories | idea | no external link or Wikipedia reference |
| BCG-unresponsive | term | no external link or Wikipedia reference |
| BCMA-directed therapy → GPRC5D-directed therapy | pairing | no external link or Wikipedia reference |
| BCR::ABL1 TKI + blinatumomab (chemotherapy-free Ph+ ALL) | pairing | no external link or Wikipedia reference |
| Beatriz Castelo | person | no external link or Wikipedia reference |
| Behnam Badie | person | no external link or Wikipedia reference |
| Benjamin Besse | person | no external link or Wikipedia reference |
| Benjamin L. Ebert | person | no external link or Wikipedia reference |
| Benjamin Solomon | person | no external link or Wikipedia reference |
| Bert Vogelstein | person | no external link or Wikipedia reference |
| Beta PRRT → alpha PRRT | pairing | no external link or Wikipedia reference |
| Beta radioligand → alpha radioligand | pairing | no external link or Wikipedia reference |
| Bethesda category (thyroid cytology) | term | no external link or Wikipedia reference |
| BILCAP | trial | no external link or Wikipedia reference |
| Binghe Xu | person | no external link or Wikipedia reference |
| Biobanking and tissue procurement | technology | no external link or Wikipedia reference |
| Biochemical recurrence (BCR) | term | no external link or Wikipedia reference |
| Biomarker-directed first-line quadruplets in gastric cancer | idea | no external link or Wikipedia reference |
| Biomarker-guided cardioprotection for everyone on cardiotoxic cancer therapy | idea | no external link or Wikipedia reference |
| Biomarker-selected adjuvant therapy in RCC (ctDNA, CAIX PET, gene signatures) | idea | no external link or Wikipedia reference |
| Biopsy the one lesion that is growing while the others shrink | idea | no external link or Wikipedia reference |
| BIOSECURE Act | term | no external link or Wikipedia reference |
| Biosimilar-first defaults and payment parity in every cancer day unit | idea | no external link or Wikipedia reference |
| Bispecific ADC | technology | no external link or Wikipedia reference |
| Bispecific antibodies that engage macrophages instead of T cells | idea | no external link or Wikipedia reference |
| Bladder preservation for MIBC after perioperative EV + pembrolizumab complete response | idea | no external link or Wikipedia reference |
| Blinatumomab added to frontline chemotherapy | pairing | no external link or Wikipedia reference |
| Blinded independent central review (BICR) | term | no external link or Wikipedia reference |
| Block the chemical switch that lets cells hide from treatment | idea | no external link or Wikipedia reference |
| Block the complement signal that recruits tumour-protecting cells | idea | no external link or Wikipedia reference |
| Block the recycling that keeps dormant cells alive | idea | no external link or Wikipedia reference |
| Block the survival signals the tumour's neighbours provide | idea | no external link or Wikipedia reference |
| Blood EBV DNA screening for nasopharyngeal cancer across southern China and Southeast Asia | idea | no external link or Wikipedia reference |
| Blood-based HCC surveillance to replace six-monthly ultrasound | idea | no external link or Wikipedia reference |
| Blood-based pancreatic cancer detection in new-onset diabetes | idea | no external link or Wikipedia reference |
| Blunt the inflammation that wakes sleeping cancer cells | idea | no external link or Wikipedia reference |
| Bob T. Li | person | no external link or Wikipedia reference |
| Bounties for documented failed replications of high-impact findings | idea | no external link or Wikipedia reference |
| Bradley E. Bernstein | person | no external link or Wikipedia reference |
| BRAF inhibitor + MEK inhibitor | pairing | no external link or Wikipedia reference |
| BRAF/MEK inhibition → surgery in anaplastic thyroid cancer | pairing | no external link or Wikipedia reference |
| BRAF/MEK plus PD-1 blockade as standard for BRAF-mutant anaplastic thyroid cancer | idea | no external link or Wikipedia reference |
| Break the neutrophil DNA nets that catch tumour cells after surgery | idea | no external link or Wikipedia reference |
| Break up the liquid droplets where oncogenic transcription happens | idea | no external link or Wikipedia reference |
| Breakthrough Therapy / Priority Review / Priority Voucher | term | no external link or Wikipedia reference |
| Brigitte C. Widemann | person | no external link or Wikipedia reference |
| Broad research consent as a routine step of the cancer pathway | idea | no external link or Wikipedia reference |
| Bruce L. Levine | person | no external link or Wikipedia reference |
| Bruce W. Stillman | person | no external link or Wikipedia reference |
| BTK degraders to pre-empt resistance in frontline CLL | idea | no external link or Wikipedia reference |
| BTK inhibitor + venetoclax, fixed duration | pairing | no external link or Wikipedia reference |
| Bud Romine | person | no external link or Wikipedia reference |
| Build a human model of the barrier that guards the brain fluid | idea | no external link or Wikipedia reference |
| Build laboratory models of the organs cancer spreads to | idea | no external link or Wikipedia reference |
| Build polygenic scores that work in every ancestry before deploying any | idea | no external link or Wikipedia reference |
| Build Western ytterbium-176 enrichment so lutetium-177 has more than one supplier | idea | no external link or Wikipedia reference |
| Bundled episode payments for cancer care with bonuses for guideline concordance | idea | no external link or Wikipedia reference |
| Burden-matched funding for trials led in low- and middle-income countries | idea | no external link or Wikipedia reference |
| Buy out the patent on a curative cancer drug and sell it at generic prices | idea | no external link or Wikipedia reference |
| Byoung Chul Cho | person | no external link or Wikipedia reference |
| Bystander effect (ADC) | term | no external link or Wikipedia reference |
| Cadonilimab | drug | no external link or Wikipedia reference |
| Caetano Reis e Sousa | person | no external link or Wikipedia reference |
| Caicun Zhou | person | no external link or Wikipedia reference |
| CAIX PET (89Zr-girentuximab) | technology | no external link or Wikipedia reference |
| CAIX theranostics: 89Zr-girentuximab PET and 177Lu/225Ac-girentuximab therapy | idea | no external link or Wikipedia reference |
| Camizestrant | drug | no external link or Wikipedia reference |
| Camrelizumab + rivoceranib | drug | no external link or Wikipedia reference |
| Can MYC be drugged directly, and will patients tolerate it? | idea | no external link or Wikipedia reference |
| Can T-DXd alone cure early HER2-positive disease? | idea | no external link or Wikipedia reference |
| Cancer interception vaccines for high-risk carriers | idea | no external link or Wikipedia reference |
| Cancer registries and population surveillance | technology | no external link or Wikipedia reference |
| Cancer risk scores running automatically in GP records to prompt urgent referral | idea | no external link or Wikipedia reference |
| Cancer variant knowledgebases and molecular tumour boards | technology | no external link or Wikipedia reference |
| Cancer warnings on alcohol labels, evaluated as a natural experiment | idea | no external link or Wikipedia reference |
| Candace S. Johnson | person | no external link or Wikipedia reference |
| Cap public prices for new cancer drugs to tiers of the ESMO and ASCO value scales | idea | no external link or Wikipedia reference |
| Capecitabine + temozolomide (CAPTEM) | drug | no external link or Wikipedia reference |
| Capture diet, fibre and antibiotic exposure in every immunotherapy pivotal trial | idea | no external link or Wikipedia reference |
| CAR-NK & CAR-macrophage | technology | no external link or Wikipedia reference |
| CAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target) | technology | no external link or Wikipedia reference |
| Cardiometabolic screening and treatment for survivors on long-term hormone therapy | idea | no external link or Wikipedia reference |
| Caregiver training and respite as a covered service in cancer care for older patients | idea | no external link or Wikipedia reference |
| Carl H. June | person | no external link or Wikipedia reference |
| Carlos Barrios | person | no external link or Wikipedia reference |
| Caroline Dive | person | no external link or Wikipedia reference |
| Carsten Bokemeyer | person | no external link or Wikipedia reference |
| Carsten Denkert | person | no external link or Wikipedia reference |
| Cash for transport and food to stop families abandoning curative treatment | idea | no external link or Wikipedia reference |
| Catch wasting early with a smart scale and a step counter | idea | no external link or Wikipedia reference |
| Catch-up HPV vaccination for men to prevent throat cancer | idea | no external link or Wikipedia reference |
| Caution: bevacizumab-based regimens with untreated varices | pairing | no external link or Wikipedia reference |
| Caution: bleomycin lung toxicity, especially with brentuximab or G-CSF | pairing | no external link or Wikipedia reference |
| Caution: checkpoint inhibitors in first-line ovarian cancer | pairing | no external link or Wikipedia reference |
| Caution: chemoimmunotherapy in del(17p)/TP53 CLL | pairing | no external link or Wikipedia reference |
| Caution: cumulative anthracycline dose and the heart | pairing | no external link or Wikipedia reference |
| Caution: de-escalating radiation on HPV status alone | pairing | no external link or Wikipedia reference |
| Caution: DXd ADC + agents with pneumonitis risk | pairing | no external link or Wikipedia reference |
| Caution: ibrutinib in patients with cardiac risk | pairing | no external link or Wikipedia reference |
| Caution: IL-2 added to anti-GD2 therapy | pairing | no external link or Wikipedia reference |
| Caution: inotuzumab before transplant (veno-occlusive disease) | pairing | no external link or Wikipedia reference |
| Caution: LAG-3 blockade outside active disease | pairing | no external link or Wikipedia reference |
| Caution: minimally invasive radical hysterectomy for early cervical cancer | pairing | no external link or Wikipedia reference |
| Caution: PD-1 rechallenge after progression on immunotherapy (RCC) | pairing | no external link or Wikipedia reference |
| Caution: T-cell redirectors and infections | pairing | no external link or Wikipedia reference |
| Caution: TIGIT + PD-(L)1 blockade | pairing | no external link or Wikipedia reference |
| Caution: TOP1 ADC immediately after TOP1 ADC | pairing | no external link or Wikipedia reference |
| CD20 bispecific + CD79b ADC (mosunetuzumab + polatuzumab) | pairing | no external link or Wikipedia reference |
| CD30 CAR-T for multiply relapsed Hodgkin lymphoma | idea | no external link or Wikipedia reference |
| CD38 antibody added to PI-IMiD-dex (quadruplet induction) | pairing | no external link or Wikipedia reference |
| CD8 PET to stop or switch immunotherapy early | idea | no external link or Wikipedia reference |
| CDK4-selective inhibitors as the new first-line backbone | idea | no external link or Wikipedia reference |
| CDK4/6 inhibitor + endocrine therapy | pairing | no external link or Wikipedia reference |
| CDMO (contract development and manufacturing organisation) | term | no external link or Wikipedia reference |
| Cell of origin (GCB vs ABC) | term | no external link or Wikipedia reference |
| Cell Therapy | section | no external link or Wikipedia reference |
| Cell therapy roadmap: CD19 CAR-T → solid tumours → in vivo CAR | roadmap | no external link or Wikipedia reference |
| Cell-therapy orchestration and chain-of-identity software | technology | no external link or Wikipedia reference |
| Cell-therapy release and potency testing | technology | no external link or Wikipedia reference |
| Certified decision aids required for every preference-sensitive cancer decision | idea | no external link or Wikipedia reference |
| Changsong Qi | person | no external link or Wikipedia reference |
| Charles D. Blanke | person | no external link or Wikipedia reference |
| Charles E. Geyer Jr. | person | no external link or Wikipedia reference |
| Charles L. Sawyers | person | no external link or Wikipedia reference |
| Charles Swanton | person | no external link or Wikipedia reference |
| Charu Aggarwal | person | no external link or Wikipedia reference |
| Cheap DNA fragment-pattern blood test as a first sieve before expensive cancer tests | idea | no external link or Wikipedia reference |
| Cheap perioperative beta-blocker plus anti-inflammatory to blunt surgical stress | idea | no external link or Wikipedia reference |
| Check whether a tumour can still show itself to the immune system | idea | no external link or Wikipedia reference |
| Chemo-immunotherapy induction → maintenance intensification (SCLC) | pairing | no external link or Wikipedia reference |
| Chemotherapy | section | no external link or Wikipedia reference |
| Chemotherapy + PD-1/PD-L1 blockade, first-line advanced endometrial cancer | pairing | no external link or Wikipedia reference |
| Chemotherapy-free Hodgkin lymphoma: brentuximab + PD-1 in early stage | idea | no external link or Wikipedia reference |
| Cheryl L. Willman | person | no external link or Wikipedia reference |
| Christian Blank | person | no external link or Wikipedia reference |
| Christine E. Brown | person | no external link or Wikipedia reference |
| Christine H. Chung | person | no external link or Wikipedia reference |
| Christof von Kalle | person | no external link or Wikipedia reference |
| Christophe Le Tourneau | person | no external link or Wikipedia reference |
| Christopher Lord | person | no external link or Wikipedia reference |
| Christopher R. Flowers | person | no external link or Wikipedia reference |
| Christopher R. Vakoc | person | no external link or Wikipedia reference |
| Circulating tumour cell clearance as the phase 2 gate for anti-metastatic drugs | idea | no external link or Wikipedia reference |
| Circulating tumour HPV DNA (ctHPV-DNA) | technology | no external link or Wikipedia reference |
| CL2A | term | no external link or Wikipedia reference |
| Claus Belka | person | no external link or Wikipedia reference |
| CLDN18.2 antibody first line → CLDN18.2 ADC or CAR-T on progression | pairing | no external link or Wikipedia reference |
| Clear the suppressive neutrophils out of pancreatic tumours first | idea | no external link or Wikipedia reference |
| Clear the zombie cells left behind by chemotherapy and radiotherapy | idea | no external link or Wikipedia reference |
| Clemens Kratochwil | person | no external link or Wikipedia reference |
| Clifford A. Hudis | person | no external link or Wikipedia reference |
| Clinical complete response (cCR) | term | no external link or Wikipedia reference |
| Clinical NGS bioinformatics and variant interpretation | technology | no external link or Wikipedia reference |
| Clinical trial software (EDC, eCOA, CTMS, RTSM) | technology | no external link or Wikipedia reference |
| Closed automated cell-therapy manufacturing | technology | no external link or Wikipedia reference |
| Collect and freeze T cells at diagnosis for high-risk patients, before chemotherapy | idea | no external link or Wikipedia reference |
| Combination baskets defined by resistance mechanism rather than by cancer type | idea | no external link or Wikipedia reference |
| Combined positive score (CPS) | term | no external link or Wikipedia reference |
| Community health workers and trusted local organisations paid to recruit for trials | idea | no external link or Wikipedia reference |
| Community health workers trained in cancer triage, navigation and home palliative care | idea | no external link or Wikipedia reference |
| Community health workers with smartphone AI screen for mouth cancer in South Asia | idea | no external link or Wikipedia reference |
| Community oncology and site networks | technology | no external link or Wikipedia reference |
| Community pharmacies as one-stop cancer prevention hubs | idea | no external link or Wikipedia reference |
| Community-tailored HPV vaccine confidence campaigns with school-based delivery | idea | no external link or Wikipedia reference |
| Compact FLASH and proton systems at the price of a conventional linac | idea | no external link or Wikipedia reference |
| Companion diagnostic | term | no external link or Wikipedia reference |
| Comparability by design: a digital twin and sentinel panel for cell process changes | idea | no external link or Wikipedia reference |
| Competing sponsors share one control arm in the same indication | idea | no external link or Wikipedia reference |
| Conditional approvals that lapse automatically if the confirmatory trial is late | idea | no external link or Wikipedia reference |
| Confirm low-dose olanzapine for appetite and weight in advanced cancer worldwide | idea | no external link or Wikipedia reference |
| Confirm or refute the harm of antioxidant supplements during chemotherapy | idea | no external link or Wikipedia reference |
| Confirm ultra-low-dose immunotherapy so it can be afforded where most patients live | idea | no external link or Wikipedia reference |
| Consensus molecular subtypes (CMS1-4) | term | no external link or Wikipedia reference |
| Continuous prospective validation for every oncology AI tool after deployment | idea | no external link or Wikipedia reference |
| Continuous-flow synthesis of ultra-potent ADC payloads to ease the capacity squeeze | idea | no external link or Wikipedia reference |
| Contract research organisations (CROs) | technology | no external link or Wikipedia reference |
| Controlled feeding trials to separate ultra-processing from calories | idea | no external link or Wikipedia reference |
| Costas A. Lyssiotis | person | no external link or Wikipedia reference |
| Covalent chemistry for the RAS mutations that still have no drug | idea | no external link or Wikipedia reference |
| Coverage-with-evidence registries for MR-guided and adaptive radiotherapy | idea | no external link or Wikipedia reference |
| Credentialed diaspora oncologists staffing remote tumour boards for home-country hospitals | idea | no external link or Wikipedia reference |
| Cretostimogene grenadenorepvec | drug | no external link or Wikipedia reference |
| CROSS chemoradiation → surgery → adjuvant nivolumab if residual disease | pairing | no external link or Wikipedia reference |
| Cryopreservation and cell-therapy cold chain | technology | no external link or Wikipedia reference |
| Crystal L. Mackall | person | no external link or Wikipedia reference |
| ctDNA KIT genotyping → TKI selection in GIST | pairing | no external link or Wikipedia reference |
| ctDNA monitoring in lymphoma (PhasED-seq, clonoSEQ) | technology | no external link or Wikipedia reference |
| ctDNA MRD → adjuvant therapy decision | pairing | no external link or Wikipedia reference |
| ctDNA-guided adjuvant therapy as the default in stage II-III colon cancer | idea | no external link or Wikipedia reference |
| ctDNA-guided adjuvant therapy in stage II-III melanoma | idea | no external link or Wikipedia reference |
| ctDNA-guided dose holidays for lung cancer targeted therapy | idea | no external link or Wikipedia reference |
| ctDNA-guided duration of PARP maintenance | idea | no external link or Wikipedia reference |
| ctDNA-guided escalation and de-escalation in frontline DLBCL | idea | no external link or Wikipedia reference |
| ctDNA-guided switching among FGFR inhibitors | idea | no external link or Wikipedia reference |
| ctDNA-triggered escalation in early TNBC | idea | no external link or Wikipedia reference |
| ctHPV-DNA-adapted de-escalation of chemoradiation | idea | no external link or Wikipedia reference |
| Cure hepatitis C in prisons and drug services, and enrol the cured in liver cancer surveillance | idea | no external link or Wikipedia reference |
| Cut off the emergency programme cancer cells use to survive treatment | idea | no external link or Wikipedia reference |
| Cut the nerve supply to tumours with old drugs | idea | no external link or Wikipedia reference |
| Dae Ho Lee | person | no external link or Wikipedia reference |
| Daniel A. Haber | person | no external link or Wikipedia reference |
| David A. Tuveson | person | no external link or Wikipedia reference |
| David B. Solit | person | no external link or Wikipedia reference |
| David Cameron | person | no external link or Wikipedia reference |
| David Cunningham | person | no external link or Wikipedia reference |
| David L. Porter | person | no external link or Wikipedia reference |
| Dawn L. Hershman | person | no external link or Wikipedia reference |
| De-acidify the tumour so T cells can work in it | idea | no external link or Wikipedia reference |
| Deauville five-point scale | term | no external link or Wikipedia reference |
| Deborah Watkins Bruner | person | no external link or Wikipedia reference |
| Debu Tripathy | person | no external link or Wikipedia reference |
| Decentralised and hybrid clinical trials | technology | no external link or Wikipedia reference |
| Decipher Prostate | drug | no external link or Wikipedia reference |
| Decision aids built into the record for every preference-sensitive cancer choice | idea | no external link or Wikipedia reference |
| Decision support that cites the exact trial and guideline line it relies on | idea | no external link or Wikipedia reference |
| Dedicated cohorts for patients with performance status 2 in first-line trials | idea | no external link or Wikipedia reference |
| Default fertility preservation referral for every patient under 40 before treatment | idea | no external link or Wikipedia reference |
| Degrade the damaged p53 protein rather than trying to repair it | idea | no external link or Wikipedia reference |
| Degrader-antibody conjugate (DAC) | technology | no external link or Wikipedia reference |
| Degraders for the fusion proteins that drive childhood sarcomas | idea | no external link or Wikipedia reference |
| del(17p) / TP53 aberration in CLL | term | no external link or Wikipedia reference |
| Deliver CAR-T cells straight into the fluid around the brain | idea | no external link or Wikipedia reference |
| Deliver drugs and cells to the brain through the nose | idea | no external link or Wikipedia reference |
| Denis Lacombe | person | no external link or Wikipedia reference |
| Denise A. Galloway | person | no external link or Wikipedia reference |
| Dennis J. Slamon | person | no external link or Wikipedia reference |
| Deposit trial results as structured data, not just PDFs | idea | no external link or Wikipedia reference |
| Dermoscopy, total-body photography & AI skin analysis | technology | no external link or Wikipedia reference |
| Design drug pairs where resisting one makes you vulnerable to the other | idea | no external link or Wikipedia reference |
| Design protein degraders small enough to get into the brain | idea | no external link or Wikipedia reference |
| Destroy the truncated androgen receptor that hormone drugs cannot touch | idea | no external link or Wikipedia reference |
| Detect tumours changing cell type from RNA in the blood | idea | no external link or Wikipedia reference |
| Develop drugs in children first when the target is a children's target | idea | no external link or Wikipedia reference |
| Device-agnostic public trials of ablation technologies against surgery | idea | no external link or Wikipedia reference |
| Devices & Physical Therapies | section | no external link or Wikipedia reference |
| Diagnostics & Biomarkers | section | no external link or Wikipedia reference |
| Digital batch records and AI process control to halve cell therapy batch failures | idea | no external link or Wikipedia reference |
| Digital twins for treatment selection, validated by predicting before observing | idea | no external link or Wikipedia reference |
| Digitise the nation's pathology slides and link them to outcomes | idea | no external link or Wikipedia reference |
| Dingwei Ye | person | no external link or Wikipedia reference |
| Disclose R&D and manufacturing costs of publicly funded cancer drugs to get coverage | idea | no external link or Wikipedia reference |
| Disitamab vedotin | drug | no external link or Wikipedia reference |
| DM4 | term | no external link or Wikipedia reference |
| DNA alkylator payloads | term | no external link or Wikipedia reference |
| DNA cleaver payloads (enediynes) | term | no external link or Wikipedia reference |
| DNA crosslinker payloads (PBD dimers) | term | no external link or Wikipedia reference |
| Do-Youn Oh | person | no external link or Wikipedia reference |
| Dong-Wan Kim | person | no external link or Wikipedia reference |
| Dongsheng Tu | person | no external link or Wikipedia reference |
| Dose and schedule optimisation trials specific to antibody-drug conjugates | idea | no external link or Wikipedia reference |
| Dose chemotherapy by muscle mass, not body surface area | idea | no external link or Wikipedia reference |
| Dose-finding in older and frail patients, not extrapolation from fit ones | idea | no external link or Wikipedia reference |
| Dosimetry | term | no external link or Wikipedia reference |
| Dosimetry-personalised PRRT instead of four fixed cycles | idea | no external link or Wikipedia reference |
| Double oncology capacity in low-resource settings with task-shifting and AI decision support | idea | no external link or Wikipedia reference |
| Double-hit / high-grade B-cell lymphoma | term | no external link or Wikipedia reference |
| Douglas R. Lowy | person | no external link or Wikipedia reference |
| Douglas S. Hawkins | person | no external link or Wikipedia reference |
| Drag cancer's surface and secreted proteins to the cell's recycling bin | idea | no external link or Wikipedia reference |
| Drew M. Pardoll | person | no external link or Wikipedia reference |
| Drew Weissman | person | no external link or Wikipedia reference |
| Drop mandatory fresh biopsies where blood or archival tissue would do | idea | no external link or Wikipedia reference |
| Drug Discovery Platforms | section | no external link or Wikipedia reference |
| Drug labels must state which biomarker assays were validated and how they compare | idea | no external link or Wikipedia reference |
| Drug-to-antibody ratio (DAR) | term | no external link or Wikipedia reference |
| Dual HER2 blockade | term | no external link or Wikipedia reference |
| Dual-payload ADC | technology | no external link or Wikipedia reference |
| Dual-payload ADCs in first line to prevent resistance | idea | no external link or Wikipedia reference |
| Dung T. Le | person | no external link or Wikipedia reference |
| Durvalumab + BCG in BCG-naive high-risk NMIBC | pairing | no external link or Wikipedia reference |
| DXd | term | no external link or Wikipedia reference |
| Dynamic consent with usage receipts | idea | no external link or Wikipedia reference |
| Early Detection & Screening | section | no external link or Wikipedia reference |
| Early detection roadmap: organ screening → blood tests for many cancers | roadmap | no external link or Wikipedia reference |
| Early FDG-PET response → chemotherapy omission (HER2+) | pairing | no external link or Wikipedia reference |
| Early relapse: CAR-T before transplant | pairing | no external link or Wikipedia reference |
| Earmark a fixed share of every national cancer budget for palliative care | idea | no external link or Wikipedia reference |
| Efflux-agnostic therapy for mesenchymal TNBC | idea | no external link or Wikipedia reference |
| EGFR C797S | term | no external link or Wikipedia reference |
| EGFR exon 19 deletion & L858R | term | no external link or Wikipedia reference |
| EGFR exon 20 insertion | term | no external link or Wikipedia reference |
| EGFR TKI → ADC on progression | pairing | no external link or Wikipedia reference |
| EGFR-directed bispecific + PD-1 blockade | pairing | no external link or Wikipedia reference |
| Eileen M. O'Reilly | person | no external link or Wikipedia reference |
| Electronic patient-reported outcomes and remote monitoring | technology | no external link or Wikipedia reference |
| Elena Élez | person | no external link or Wikipedia reference |
| Elena Garralda | person | no external link or Wikipedia reference |
| Eliane Piaggio | person | no external link or Wikipedia reference |
| Eliezer M. Van Allen | person | no external link or Wikipedia reference |
| Elironrasib | drug | no external link or Wikipedia reference |
| Elisabete Weiderpass | person | no external link or Wikipedia reference |
| Elizabeth M. Jaffee | person | no external link or Wikipedia reference |
| Emile Voest | person | no external link or Wikipedia reference |
| Emily K. Bergsland | person | no external link or Wikipedia reference |
| Emulate combination trials from real-world data to triage which ones to run | idea | no external link or Wikipedia reference |
| Emulate the trial in real-world data first to decide which trials to run | idea | no external link or Wikipedia reference |
| End the abstract-to-paper gap: require full results with any conference presentation | idea | no external link or Wikipedia reference |
| Endocrine resistance | term | no external link or Wikipedia reference |
| Enfortumab vedotin + pembrolizumab across the bladder cancer continuum | pairing | no external link or Wikipedia reference |
| Engineered bacteria that live in tumours and manufacture drugs there | idea | no external link or Wikipedia reference |
| Engineered immune surveillance: long-lived programmed immune cells that patrol for early cancer | idea | no external link or Wikipedia reference |
| Enrique Espinosa | person | no external link or Wikipedia reference |
| Enriqueta Felip | person | no external link or Wikipedia reference |
| Epigenetic & Transcriptional Therapy | section | no external link or Wikipedia reference |
| Epithelioid vs sarcomatoid (biphasic) mesothelioma | term | no external link or Wikipedia reference |
| Eradicate dormant cancer cells: a programme to wake and kill or lock asleep disseminated cells | idea | no external link or Wikipedia reference |
| Eric B. Haura | person | no external link or Wikipedia reference |
| Eric J. Small | person | no external link or Wikipedia reference |
| Eric R. Fearon | person | no external link or Wikipedia reference |
| Erik Sahai | person | no external link or Wikipedia reference |
| Eunice S. Wang | person | no external link or Wikipedia reference |
| Evaluate alcohol minimum unit pricing against cancer incidence | idea | no external link or Wikipedia reference |
| Evaluate clean-air policies using lung cancer in never-smokers | idea | no external link or Wikipedia reference |
| Evandro de Azambuja | person | no external link or Wikipedia reference |
| Evanthia Galanis | person | no external link or Wikipedia reference |
| Evening and weekend trial clinics for working-age patients | idea | no external link or Wikipedia reference |
| Event-free / disease-free survival (EFS, DFS, iDFS, RFS) | term | no external link or Wikipedia reference |
| Everett E. Vokes | person | no external link or Wikipedia reference |
| Every AI output logged in the record with input hash, version and clinician response | idea | no external link or Wikipedia reference |
| Every approved cancer drug ships with a public combination-readiness data pack | idea | no external link or Wikipedia reference |
| Every cancer biology PhD begins with a funded replication of a published finding | idea | no external link or Wikipedia reference |
| Every drug screen includes standard reference compounds whose performance is published | idea | no external link or Wikipedia reference |
| Every lung screening visit includes stop-smoking medicine, opt-out | idea | no external link or Wikipedia reference |
| Every pathology and genomic report ships with a signed plain-language version | idea | no external link or Wikipedia reference |
| Every patient on an accelerated-approval drug enrolled in a registry until confirmation | idea | no external link or Wikipedia reference |
| Every payer covers routine care costs for trial participants, in every country | idea | no external link or Wikipedia reference |
| Every resistance mechanism found in a patient must be rebuilt in the laboratory | idea | no external link or Wikipedia reference |
| Every routine CT scan checked by AI for early cancer signs, with a tracked follow-up pathway | idea | no external link or Wikipedia reference |
| Every screening programme must publish its overdiagnosis rate each year | idea | no external link or Wikipedia reference |
| Every tumour sequencing report lists open, nearby, matched trials pulled live | idea | no external link or Wikipedia reference |
| Evidence-based integrative oncology in every cancer centre to meet demand safely | idea | no external link or Wikipedia reference |
| Evolutionary tumour boards with a modeller in the room | idea | no external link or Wikipedia reference |
| Exercise & lifestyle oncology | technology | no external link or Wikipedia reference |
| Expert-verified translation of guideline updates into 20 languages within 30 days | idea | no external link or Wikipedia reference |
| Extend p53 reactivation beyond the Y220C mutation | idea | no external link or Wikipedia reference |
| Extended-interval immunotherapy: give checkpoint inhibitors every 8-12 weeks once stable | idea | no external link or Wikipedia reference |
| Extending sarcoma TCR-T beyond HLA-A*02 | idea | no external link or Wikipedia reference |
| External validation at five or more sites in two countries before clearance | idea | no external link or Wikipedia reference |
| Extra exclusivity for sponsors who run treatment-duration and de-escalation trials | idea | no external link or Wikipedia reference |
| F. Stephen Hodi | person | no external link or Wikipedia reference |
| Fabrice André | person | no external link or Wikipedia reference |
| Fabrice Barlesi | person | no external link or Wikipedia reference |
| Factorial dose finding for drug combinations instead of full dose of everything | idea | no external link or Wikipedia reference |
| Family history collected by app and matched to testing criteria automatically | idea | no external link or Wikipedia reference |
| Family-based H. pylori test-and-treat to prevent stomach cancer | idea | no external link or Wikipedia reference |
| FAP theranostics as a pan-cancer stromal strategy | idea | no external link or Wikipedia reference |
| FAP-2286 (177Lu / 68Ga) | drug | no external link or Wikipedia reference |
| FAPI PET as the workup for MCED positives | idea | no external link or Wikipedia reference |
| Fast-track relicensing for refugee, migrant and returning oncology professionals | idea | no external link or Wikipedia reference |
| Fc engineering / effector function | term | no external link or Wikipedia reference |
| Federated learning and privacy-preserving AI | technology | no external link or Wikipedia reference |
| Fei Ma | person | no external link or Wikipedia reference |
| Feng Wang | person | no external link or Wikipedia reference |
| Feng Zhang | person | no external link or Wikipedia reference |
| Fertility preservation offered and funded by default before gonadotoxic treatment | idea | no external link or Wikipedia reference |
| Fertility-sparing hormonal treatment of early endometrial cancer | technology | no external link or Wikipedia reference |
| FGFR2 fusions and rearrangements | term | no external link or Wikipedia reference |
| FGFR3 alterations (bladder cancer) | term | no external link or Wikipedia reference |
| Filippo de Braud | person | no external link or Wikipedia reference |
| Find E3 ligases that only tumours have, and build degraders around them | idea | no external link or Wikipedia reference |
| Find the parts of a tumour the drug never reaches | idea | no external link or Wikipedia reference |
| Fiona Blackhall | person | no external link or Wikipedia reference |
| Fix the neutrophil count rule that excludes many people of African ancestry | idea | no external link or Wikipedia reference |
| Flotufolastat F-18 | drug | no external link or Wikipedia reference |
| FLT3 inhibitor + intensive chemotherapy | pairing | no external link or Wikipedia reference |
| FLT3-ITD allelic ratio | term | no external link or Wikipedia reference |
| Flush dormant cells out of bone marrow, then kill them | idea | no external link or Wikipedia reference |
| FNCLCC grade (soft-tissue sarcoma) | term | no external link or Wikipedia reference |
| Focused-ultrasound BBB opening to deliver ADCs and radioligands to glioma | idea | no external link or Wikipedia reference |
| Focused-ultrasound blood-brain barrier opening | technology | no external link or Wikipedia reference |
| Follow every trial participant for 30 years through registry linkage | idea | no external link or Wikipedia reference |
| Forecast the next resistance mutation like the weather | idea | no external link or Wikipedia reference |
| Formal caregiver assessment and training written into every treatment plan | idea | no external link or Wikipedia reference |
| Formal shared-care agreements between oncology and family doctors, with same-day e-consult | idea | no external link or Wikipedia reference |
| FoundationOne CDx / Liquid CDx | drug | no external link or Wikipedia reference |
| Four weeks of training and nutrition before major cancer surgery, as standard | idea | no external link or Wikipedia reference |
| Fran Visco | person | no external link or Wikipedia reference |
| Francisca Vazquez | person | no external link or Wikipedia reference |
| François-Clément Bidard | person | no external link or Wikipedia reference |
| Frank McCormick | person | no external link or Wikipedia reference |
| Freddie Bray | person | no external link or Wikipedia reference |
| Frederick L. Locke | person | no external link or Wikipedia reference |
| Frederik Giesel | person | no external link or Wikipedia reference |
| Fund a biopsy at progression, every time, as standard care | idea | no external link or Wikipedia reference |
| Fund alpha emitters beyond actinium-225: lead-212, terbium-149 and astatine-211 | idea | no external link or Wikipedia reference |
| Fund investigators from under-represented communities and community sites to lead trials | idea | no external link or Wikipedia reference |
| Fund scalp cooling and hair-preserving measures for every alopecia-inducing regimen | idea | no external link or Wikipedia reference |
| Funda Meric-Bernstam | person | no external link or Wikipedia reference |
| Funder bonuses for releasing results and data within six months, negatives included | idea | no external link or Wikipedia reference |
| G12D-selective + pan-RAS(ON) inhibitor (zoldonrasib + daraxonrasib) | pairing | no external link or Wikipedia reference |
| Gad Getz | person | no external link or Wikipedia reference |
| Gary H. Lyman | person | no external link or Wikipedia reference |
| GD2 CAR-T as consolidation in high-risk neuroblastoma | idea | no external link or Wikipedia reference |
| Gedatolisib | drug | no external link or Wikipedia reference |
| Gemcitabine intravesical system (TAR-200) | drug | no external link or Wikipedia reference |
| Gemcitabine-cisplatin + PD-(L)1 blockade in biliary cancer | pairing | no external link or Wikipedia reference |
| Gene-expression assay → chemotherapy omission | pairing | no external link or Wikipedia reference |
| Generic oncology drug supply and shortage mitigation | technology | no external link or Wikipedia reference |
| Genomics cloud and secure research environments | technology | no external link or Wikipedia reference |
| Geriatric assessment | technology | no external link or Wikipedia reference |
| Geriatric assessment by default for every older patient, and trials that admit them | idea | no external link or Wikipedia reference |
| Geriatrician co-management for older patients having cancer surgery | idea | no external link or Wikipedia reference |
| Germline BRCA test → adjuvant PARP inhibitor | pairing | no external link or Wikipedia reference |
| Get every Lynch syndrome carrier onto the right dose of aspirin | idea | no external link or Wikipedia reference |
| Get the one approved appetite drug licensed beyond a single country | idea | no external link or Wikipedia reference |
| Giampaolo Tortora | person | no external link or Wikipedia reference |
| Giovanni Scambia | person | no external link or Wikipedia reference |
| Giredestrant | drug | no external link or Wikipedia reference |
| Giulio Draetta | person | no external link or Wikipedia reference |
| Giuseppe Curigliano | person | no external link or Wikipedia reference |
| Give immunotherapy in the morning | idea | no external link or Wikipedia reference |
| Give negative trials plenary slots at the big cancer conferences | idea | no external link or Wikipedia reference |
| GLP-1 drugs to reverse endometrial precancer in women with obesity | idea | no external link or Wikipedia reference |
| GLP-1 receptor agonists as adjuvant weight-loss therapy in HR-positive breast cancer | idea | no external link or Wikipedia reference |
| Glucose monitor data as an early pancreatic cancer signal | idea | no external link or Wikipedia reference |
| Go back to families of women who died of ovarian cancer and offer BRCA testing | idea | no external link or Wikipedia reference |
| Golcadomide | drug | no external link or Wikipedia reference |
| Government reinsurance for phase 2 failures of first-in-class cancer drugs | idea | no external link or Wikipedia reference |
| Grant extra exclusivity only in exchange for binding low prices in poorer countries | idea | no external link or Wikipedia reference |
| Grant McArthur | person | no external link or Wikipedia reference |
| Grant progress reports must list what did not work | idea | no external link or Wikipedia reference |
| Group trials by broken mechanism, not by organ or single mutation | idea | no external link or Wikipedia reference |
| Grow blood-borne tumour cells to test drugs on the cells that actually spread | idea | no external link or Wikipedia reference |
| Grow each trial patient's tumour as organoids to decide which platform arm opens next | idea | no external link or Wikipedia reference |
| Grow immune command posts inside tumours | idea | no external link or Wikipedia reference |
| Grow models from tumour cells in the blood when a biopsy is impossible | idea | no external link or Wikipedia reference |
| Grow tumour organoids together with the patient's own immune cells | idea | no external link or Wikipedia reference |
| Guidelines list the open trials at every decision point, updated monthly | idea | no external link or Wikipedia reference |
| Gunter von Minckwitz | person | no external link or Wikipedia reference |
| Hagen F. Kennecke | person | no external link or Wikipedia reference |
| Hagop M. Kantarjian | person | no external link or Wikipedia reference |
| Hans-Gustaf Ljunggren | person | no external link or Wikipedia reference |
| Hans-Peter Kiem | person | no external link or Wikipedia reference |
| Harmonise Europe's hospital exemption for academic cell therapies, with one registry | idea | no external link or Wikipedia reference |
| Haruhiko Fukuda | person | no external link or Wikipedia reference |
| Hatem Soliman | person | no external link or Wikipedia reference |
| Head-to-head bispecific vs CAR-T in second-line LBCL | idea | no external link or Wikipedia reference |
| Heather A. Wakelee | person | no external link or Wikipedia reference |
| Helena A. Yu | person | no external link or Wikipedia reference |
| HER2 ADCs as standard for HER2-positive serous endometrial cancer | idea | no external link or Wikipedia reference |
| HER2 PET | technology | no external link or Wikipedia reference |
| HER2 sequence in gastric cancer: zanidatamab/trastuzumab + chemo ± PD-1 → T-DXd | pairing | no external link or Wikipedia reference |
| HER2-low and HER2-ultralow | term | no external link or Wikipedia reference |
| HER2-low scoring → T-DXd | pairing | no external link or Wikipedia reference |
| HER2-positive brain metastases | term | no external link or Wikipedia reference |
| Hermann Brenner | person | no external link or Wikipedia reference |
| High-grade serous ovarian carcinoma (HGSOC) | term | no external link or Wikipedia reference |
| High-risk cytogenetics (myeloma) | term | no external link or Wikipedia reference |
| High-throughput screening and DNA-encoded libraries | technology | no external link or Wikipedia reference |
| HIPEC at interval cytoreductive surgery | pairing | no external link or Wikipedia reference |
| Histologic transformation | term | no external link or Wikipedia reference |
| Histology → first-line choice in mesothelioma | pairing | no external link or Wikipedia reference |
| Histology automation and IHC autostainers | technology | no external link or Wikipedia reference |
| Histotype-tailored therapy | term | no external link or Wikipedia reference |
| Hitoshi Nakagama | person | no external link or Wikipedia reference |
| HLA-A*02:01 restriction | term | no external link or Wikipedia reference |
| Ho Yeong Lim | person | no external link or Wikipedia reference |
| Hold organoid drug tests to the same standard as a diagnostic test | idea | no external link or Wikipedia reference |
| Home administration of selected chemotherapy and immunotherapy for older and frail patients | idea | no external link or Wikipedia reference |
| Home end-of-life care kits and trained family carers where no hospice exists | idea | no external link or Wikipedia reference |
| Hope S. Rugo | person | no external link or Wikipedia reference |
| Hormonal Therapy | section | no external link or Wikipedia reference |
| Hormone tablets instead of surgery for small breast cancers in the frail over-80s | idea | no external link or Wikipedia reference |
| Hospital-at-home for oncology: treating low-risk febrile neutropenia and dehydration at home | idea | no external link or Wikipedia reference |
| Hospital-based CAR-T manufacturing at cost through a public network | idea | no external link or Wikipedia reference |
| Hospital-exemption cell therapies at scale, backed by a shared registry | idea | no external link or Wikipedia reference |
| Hospital-funded protected time for clinician-scientists, repaid by trial revenue | idea | no external link or Wikipedia reference |
| Hot vs cold tumours | term | no external link or Wikipedia reference |
| Howard I. Scher | person | no external link or Wikipedia reference |
| HPV circulating tumour DNA to guide cervical cancer therapy | idea | no external link or Wikipedia reference |
| HRD & BRCA testing | technology | no external link or Wikipedia reference |
| Humanised mice with an immune system matched to the tumour donor | idea | no external link or Wikipedia reference |
| Hydrophilic next-generation linkers (TMALIN, Dolaflexin, sulfonyl-pyrimidine, PEG-containing) | term | no external link or Wikipedia reference |
| Hye Ryun Kim | person | no external link or Wikipedia reference |
| Iain Foulkes | person | no external link or Wikipedia reference |
| Ian Cree | person | no external link or Wikipedia reference |
| Iberdomide | drug | no external link or Wikipedia reference |
| ICANS (neurotoxicity) | term | no external link or Wikipedia reference |
| Ifinatamab deruxtecan | drug | no external link or Wikipedia reference |
| Igor Puzanov | person | no external link or Wikipedia reference |
| Imaging | section | no external link or Wikipedia reference |
| Imaging core labs and central review | technology | no external link or Wikipedia reference |
| IMDC risk → first-line regimen choice (RCC) | pairing | no external link or Wikipedia reference |
| IMDC risk groups (favourable / intermediate / poor) | term | no external link or Wikipedia reference |
| Imlunestrant | drug | no external link or Wikipedia reference |
| Immune-stimulating antibody conjugate (ISAC) | technology | no external link or Wikipedia reference |
| Immunotherapy | section | no external link or Wikipedia reference |
| Immunotherapy before surgery rather than with chemoradiation (HNSCC) | pairing | no external link or Wikipedia reference |
| Immunotherapy downstaging to transplant with a safe washout | idea | no external link or Wikipedia reference |
| Immunotherapy first, then BRAF/MEK (BRAF-mutant melanoma) | pairing | no external link or Wikipedia reference |
| Immunotherapy roadmap: Coley's toxins → checkpoint inhibitors → engineered immunity | roadmap | no external link or Wikipedia reference |
| Implant a tiny device that tests twenty drugs inside the patient's own tumour | idea | no external link or Wikipedia reference |
| In silico trials to choose the dose before the first patient | idea | no external link or Wikipedia reference |
| In silico trials to prioritise combinations, scored against later real trials | idea | no external link or Wikipedia reference |
| In vivo CAR-T | technology | no external link or Wikipedia reference |
| In vivo CAR-T against solid-tumour antigens | idea | no external link or Wikipedia reference |
| In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma | idea | no external link or Wikipedia reference |
| In vivo CAR-T manufactured and priced like a generic biologic | idea | no external link or Wikipedia reference |
| Independent replication of the key experiment before first-in-human academic trials | idea | no external link or Wikipedia reference |
| Induction chemotherapy → chemoradiation (locally advanced cervical cancer) | pairing | no external link or Wikipedia reference |
| Infusion pumps, ports, and ambulatory chemotherapy devices | technology | no external link or Wikipedia reference |
| Inhaled immune therapy to make the lung hostile to arriving tumour cells | idea | no external link or Wikipedia reference |
| Inoculate newly diagnosed patients against common cancer scams | idea | no external link or Wikipedia reference |
| Instruct tumour cells to make antibodies against their own oncoprotein | idea | no external link or Wikipedia reference |
| Intercept cancer at the field stage | idea | no external link or Wikipedia reference |
| Intercepting late recurrence with ctDNA surveillance and oral SERDs | idea | no external link or Wikipedia reference |
| Intermittent or stop-and-restart nirogacestat in desmoid tumours | idea | no external link or Wikipedia reference |
| Irving L. Weissman | person | no external link or Wikipedia reference |
| Is aneuploidy itself a druggable vulnerability? | idea | no external link or Wikipedia reference |
| Ivonescimab | drug | no external link or Wikipedia reference |
| Jae H. Park | person | no external link or Wikipedia reference |
| Jae Lyun Lee | person | no external link or Wikipedia reference |
| Jaime Feliu | person | no external link or Wikipedia reference |
| Jame Abraham | person | no external link or Wikipedia reference |
| James L. Gulley | person | no external link or Wikipedia reference |
| James Larkin | person | no external link or Wikipedia reference |
| James P. Allison | person | no external link or Wikipedia reference |
| Janet Dancey | person | no external link or Wikipedia reference |
| Jaroslaw P. Maciejewski | person | no external link or Wikipedia reference |
| Javier Cortés | person | no external link or Wikipedia reference |
| Jean-Charles Soria | person | no external link or Wikipedia reference |
| Jean-Yves Blay | person | no external link or Wikipedia reference |
| Jeeyun Lee | person | no external link or Wikipedia reference |
| Jennifer K. Litton | person | no external link or Wikipedia reference |
| Jeremie Calais | person | no external link or Wikipedia reference |
| Jie He | person | no external link or Wikipedia reference |
| Jie Wang | person | no external link or Wikipedia reference |
| Jin Li | person | no external link or Wikipedia reference |
| Jing Huang | person | no external link or Wikipedia reference |
| Joaquín Arribas | person | no external link or Wikipedia reference |
| Johann de Bono | person | no external link or Wikipedia reference |
| Johannes Czernin | person | no external link or Wikipedia reference |
| John E. Dick | person | no external link or Wikipedia reference |
| John F. DiPersio | person | no external link or Wikipedia reference |
| John Haanen | person | no external link or Wikipedia reference |
| John V. Heymach | person | no external link or Wikipedia reference |
| Jonas Bergh | person | no external link or Wikipedia reference |
| Joohyuk Sohn | person | no external link or Wikipedia reference |
| Josep Tabernero | person | no external link or Wikipedia reference |
| Joseph Trapani | person | no external link or Wikipedia reference |
| Joshua Brody | person | no external link or Wikipedia reference |
| Journals check that data links actually work, and flag papers whose data vanish | idea | no external link or Wikipedia reference |
| Judge funding programme officers on burden alignment and trials completed | idea | no external link or Wikipedia reference |
| Judge skin cancer AI by the thick melanomas it prevents, not the thin ones it finds | idea | no external link or Wikipedia reference |
| Judy E. Garber | person | no external link or Wikipedia reference |
| Julie R. Brahmer | person | no external link or Wikipedia reference |
| Julie R. Park | person | no external link or Wikipedia reference |
| Jun Ma | person | no external link or Wikipedia reference |
| Jürgen Debus | person | no external link or Wikipedia reference |
| Jürgen Wolf | person | no external link or Wikipedia reference |
| Justin D. Lathia | person | no external link or Wikipedia reference |
| Justin F. Gainor | person | no external link or Wikipedia reference |
| Kan Yonemori | person | no external link or Wikipedia reference |
| Karim Fizazi | person | no external link or Wikipedia reference |
| Katherine K. Matthay | person | no external link or Wikipedia reference |
| Kathy S. Albain | person | no external link or Wikipedia reference |
| Keep a freshly removed tumour alive on a pump and test drugs in it | idea | no external link or Wikipedia reference |
| Keep dormant cells asleep instead of trying to kill them | idea | no external link or Wikipedia reference |
| Keep them asleep: dormancy maintenance as adjuvant therapy | idea | no external link or Wikipedia reference |
| Keith T. Flaherty | person | no external link or Wikipedia reference |
| Kellie N. Smith | person | no external link or Wikipedia reference |
| Kenneth C. Anderson | person | no external link or Wikipedia reference |
| Kenneth W. Kinzler | person | no external link or Wikipedia reference |
| Kevan M. Shokat | person | no external link or Wikipedia reference |
| Kevin Harrington | person | no external link or Wikipedia reference |
| Kidney and liver impairment dosing studies completed before approval, not years after | idea | no external link or Wikipedia reference |
| Kill combination arms early using circulating tumour DNA, before waiting for scans | idea | no external link or Wikipedia reference |
| Kill drug-tolerant persisters through ferroptosis | idea | no external link or Wikipedia reference |
| Kill the sleeping survivor cells with iron-dependent cell death | idea | no external link or Wikipedia reference |
| Klaus Pantel | person | no external link or Wikipedia reference |
| Kohei Shitara | person | no external link or Wikipedia reference |
| Koichi Goto | person | no external link or Wikipedia reference |
| KRAS G12C inhibitor + anti-EGFR antibody (colorectal) | pairing | no external link or Wikipedia reference |
| KRAS roadmap: undruggable → G12C → pan-RAS | roadmap | no external link or Wikipedia reference |
| Kristian Helin | person | no external link or Wikipedia reference |
| Kumar Prabhash | person | no external link or Wikipedia reference |
| Label every biomarker claim with an evidence phase, like drugs | idea | no external link or Wikipedia reference |
| Label every targetable mutation as truncal or branch on the report | idea | no external link or Wikipedia reference |
| Lars Bullinger | person | no external link or Wikipedia reference |
| Late recurrence | term | no external link or Wikipedia reference |
| Laura J. Esserman | person | no external link or Wikipedia reference |
| Laurence Zitvogel | person | no external link or Wikipedia reference |
| Lay trial navigators funded per centre, evaluated in a randomised trial | idea | no external link or Wikipedia reference |
| Lecia V. Sequist | person | no external link or Wikipedia reference |
| Leif W. Ellisen | person | no external link or Wikipedia reference |
| Lenvatinib + pembrolizumab (pMMR endometrial cancer after platinum) | pairing | no external link or Wikipedia reference |
| Let clinics contact relatives directly when a cancer gene is found | idea | no external link or Wikipedia reference |
| Let patients themselves donate their records and samples for ultra-rare cancers | idea | no external link or Wikipedia reference |
| Let the trial learn: response-adaptive allocation across many combination arms | idea | no external link or Wikipedia reference |
| Letetresgene autoleucel | drug | no external link or Wikipedia reference |
| LGR5 | term | no external link or Wikipedia reference |
| Li Ding | person | no external link or Wikipedia reference |
| Li Zhang | person | no external link or Wikipedia reference |
| Lillian L. Siu | person | no external link or Wikipedia reference |
| Limit secondary patents and pay-for-delay so cancer generics arrive on time | idea | no external link or Wikipedia reference |
| Limited-stage vs extensive-stage (SCLC) | term | no external link or Wikipedia reference |
| Lin Shen | person | no external link or Wikipedia reference |
| Lines of therapy | term | no external link or Wikipedia reference |
| Link bariatric and GLP-1 registries to cancer registries in every country that has both | idea | no external link or Wikipedia reference |
| Link single-cell and spatial tumour atlases to clinical outcomes | idea | no external link or Wikipedia reference |
| Linked human organ chips to predict side effects before people are dosed | idea | no external link or Wikipedia reference |
| Linked prescribing and outcome data to find drug interactions with cancer therapy | idea | no external link or Wikipedia reference |
| Linvoseltamab | drug | no external link or Wikipedia reference |
| Listed companies must disclose top-line data, not just 'did not meet endpoint' | idea | no external link or Wikipedia reference |
| Live guideline-concordance dashboards for every tumour board, generated from the record | idea | no external link or Wikipedia reference |
| Live tracker of the lag from first approval to real availability in every country | idea | no external link or Wikipedia reference |
| Living plain-language evidence summaries for every common cancer question in 20 languages | idea | no external link or Wikipedia reference |
| Living, machine-readable guidelines pushed to the point of care in every country | idea | no external link or Wikipedia reference |
| Locally prepared oral morphine solution, licensed for nurse prescribing | idea | no external link or Wikipedia reference |
| Lock the biomarker cut-off before phase 3, and publish it | idea | no external link or Wikipedia reference |
| Long-read sequencing (PacBio, Oxford Nanopore) | technology | no external link or Wikipedia reference |
| Look for the resistant sub-population before the first dose | idea | no external link or Wikipedia reference |
| Lori J. Pierce | person | no external link or Wikipedia reference |
| Losartan to loosen the stroma of pancreatic cancer before chemotherapy: a phase 3 | idea | no external link or Wikipedia reference |
| Louis M. Staudt | person | no external link or Wikipedia reference |
| Low-cost cobalt-60 brachytherapy for cervical cancer in every regional centre | idea | no external link or Wikipedia reference |
| Low-dose tamoxifen for high-risk women, prescribed by pharmacists and nurses | idea | no external link or Wikipedia reference |
| Low-grade serous ovarian cancer (LGSOC) | term | no external link or Wikipedia reference |
| Low-risk differentiated thyroid cancer (ATA risk) | term | no external link or Wikipedia reference |
| Luis A. Diaz Jr. | person | no external link or Wikipedia reference |
| Lung screening eligibility by risk score, not pack-years, including high-risk never-smokers | idea | no external link or Wikipedia reference |
| Lynn M. Schuchter | person | no external link or Wikipedia reference |
| Macrocyclic peptides to cover protein surfaces that pills cannot | idea | no external link or Wikipedia reference |
| Major pathological response (MPR) | term | no external link or Wikipedia reference |
| Make a two-minute mouth cancer check part of every dental visit | idea | no external link or Wikipedia reference |
| Make bespoke mouse cancer models in weeks with in vivo gene editing | idea | no external link or Wikipedia reference |
| Make clonal clearance, not tumour shrinkage, a trial endpoint | idea | no external link or Wikipedia reference |
| Make every cold tumour hot: a coordinated programme to reprogramme immune-excluded tumours | idea | no external link or Wikipedia reference |
| Make in vivo metastasis screens a required step in drug discovery | idea | no external link or Wikipedia reference |
| Make post-progression sampling a condition of accelerated approval | idea | no external link or Wikipedia reference |
| Make skipping radiotherapy the default for very low-risk breast cancer | idea | no external link or Wikipedia reference |
| Make sponsors justify every trial exclusion of older and multimorbid patients | idea | no external link or Wikipedia reference |
| Making microsatellite-stable colorectal cancer immunotherapy-responsive | idea | no external link or Wikipedia reference |
| Malachi Griffith | person | no external link or Wikipedia reference |
| Maleimidocaproyl (mc), non-cleavable | term | no external link or Wikipedia reference |
| Mandatory interval-cancer audit for every blood-based screening test | idea | no external link or Wikipedia reference |
| Mandatory national virtual tumour boards for rare and complex cancers | idea | no external link or Wikipedia reference |
| Mandatory post-market performance reporting for cancer AI | idea | no external link or Wikipedia reference |
| Mandatory public reporting of vein-to-vein time and failure rate per CAR-T product | idea | no external link or Wikipedia reference |
| Mandatory radon testing when homes are sold, with subsidised mitigation | idea | no external link or Wikipedia reference |
| Mandatory real-world reporting for patients excluded from pivotal trials | idea | no external link or Wikipedia reference |
| Mandatory subgroup performance reporting for cancer AI | idea | no external link or Wikipedia reference |
| Map metabolic dependencies in the patient, not the dish | idea | no external link or Wikipedia reference |
| Map which tumour clones sit next to which immune cells before choosing therapy | idea | no external link or Wikipedia reference |
| MAPK inhibitor redifferentiation → radioiodine | pairing | no external link or Wikipedia reference |
| Marco Guzzo | person | no external link or Wikipedia reference |
| Margaret Foti | person | no external link or Wikipedia reference |
| Mariana Chavez-MacGregor | person | no external link or Wikipedia reference |
| Mark R. Litzow | person | no external link or Wikipedia reference |
| Markus Graefen | person | no external link or Wikipedia reference |
| Martine Piccart | person | no external link or Wikipedia reference |
| Masked / conditionally active ADC | technology | no external link or Wikipedia reference |
| Match each blood-detected clone to the lesion it comes from on the scan | idea | no external link or Wikipedia reference |
| Match therapy to the type of scar-forming cell in the tumour | idea | no external link or Wikipedia reference |
| Matthew D. Galsky | person | no external link or Wikipedia reference |
| Matthew Meyerson | person | no external link or Wikipedia reference |
| Matthew P. Goetz | person | no external link or Wikipedia reference |
| Max S. Wicha | person | no external link or Wikipedia reference |
| Maximilian Diehn | person | no external link or Wikipedia reference |
| mc-Val-Cit-PABC | term | no external link or Wikipedia reference |
| Measure and publish pain control rates in every cancer centre | idea | no external link or Wikipedia reference |
| Measure and treat chemo brain with objective digital cognitive testing | idea | no external link or Wikipedia reference |
| Measure blood levels of oral targeted drugs and adjust doses to a target range | idea | no external link or Wikipedia reference |
| Mechanically pulverise one tumour with ultrasound to wake the immune system | idea | no external link or Wikipedia reference |
| Medical cyclotrons, hot cells, and synthesis modules | technology | no external link or Wikipedia reference |
| Mel Greaves | person | no external link or Wikipedia reference |
| Menin inhibitor + venetoclax + azacitidine | pairing | no external link or Wikipedia reference |
| Menin inhibitors for infant KMT2A-rearranged ALL | idea | no external link or Wikipedia reference |
| MET amplification (bypass resistance) | term | no external link or Wikipedia reference |
| Metastasis prevention as a formal indication with its own trials and regulatory pathway | idea | no external link or Wikipedia reference |
| Mezigdomide | drug | no external link or Wikipedia reference |
| Michael A. Caligiuri | person | no external link or Wikipedia reference |
| Michael A. Teitell | person | no external link or Wikipedia reference |
| Michael Baumann | person | no external link or Wikipedia reference |
| Michael Hallek | person | no external link or Wikipedia reference |
| Michael Hofman | person | no external link or Wikipedia reference |
| Michael J. Morris | person | no external link or Wikipedia reference |
| Michael LeBlanc | person | no external link or Wikipedia reference |
| Michael von Bergwelt | person | no external link or Wikipedia reference |
| Michael Weller | person | no external link or Wikipedia reference |
| Michelle Mitchell | person | no external link or Wikipedia reference |
| Micro-learning pushed to community oncologists within 30 days of a practice change | idea | no external link or Wikipedia reference |
| Microbiome transplant as a routine immunotherapy adjunct | idea | no external link or Wikipedia reference |
| Miguel Martín | person | no external link or Wikipedia reference |
| Milestone prizes for first-in-class mechanisms reaching human proof of concept | idea | no external link or Wikipedia reference |
| Min-Hee Ryu | person | no external link or Wikipedia reference |
| Minimum alcohol pricing evaluated with cancer endpoints | idea | no external link or Wikipedia reference |
| Miriam Merad | person | no external link or Wikipedia reference |
| Mitchell D. Schnall | person | no external link or Wikipedia reference |
| Mobile diagnostic units that biopsy, scan and treat on the same visit | idea | no external link or Wikipedia reference |
| Mobile research units bring trial visits to rural towns | idea | no external link or Wikipedia reference |
| Model-informed individual dosing with drug-level monitoring for every oral cancer drug | idea | no external link or Wikipedia reference |
| Modern autopsy studies to measure how much silent cancer people carry | idea | no external link or Wikipedia reference |
| Modernised cobalt-60 machines as a deliberate bridge where linacs cannot be kept running | idea | no external link or Wikipedia reference |
| Molecular glues that break the MYC-MAX partnership | idea | no external link or Wikipedia reference |
| Molecular imaging roadmap: FDG → PSMA → FAP → antigen and immune PET | roadmap | no external link or Wikipedia reference |
| Molecular indolence classifiers bundled with every screening programme | idea | no external link or Wikipedia reference |
| Molecular-class-directed adjuvant therapy in endometrial cancer | idea | no external link or Wikipedia reference |
| Molecular-progression switching beyond ESR1 | idea | no external link or Wikipedia reference |
| Monitor biomarker positivity rates across labs in real time to catch assay drift | idea | no external link or Wikipedia reference |
| MRD negativity (myeloma, 10⁻⁵ / 10⁻⁶) | term | no external link or Wikipedia reference |
| MRD-guided transplant decisions in intermediate-risk AML | idea | no external link or Wikipedia reference |
| MRD-guided treatment duration in CLL | idea | no external link or Wikipedia reference |
| MRD-guided treatment-free intervals in myeloma | idea | no external link or Wikipedia reference |
| MRD-negative complete remission | term | no external link or Wikipedia reference |
| MRI surveillance replaces prophylactic cranial irradiation in SCLC | idea | no external link or Wikipedia reference |
| mRNA-delivered MYC decoy proteins instead of MYC inhibitors | idea | no external link or Wikipedia reference |
| MRTX1133 | drug | no external link or Wikipedia reference |
| Mu-Sheng Zeng | person | no external link or Wikipedia reference |
| Multi-cancer blood test as the first step for patients with non-specific symptoms | idea | no external link or Wikipedia reference |
| Multi-centre randomised animal trials before committing to a human trial | idea | no external link or Wikipedia reference |
| Multimodal prehabilitation for older patients before major cancer surgery | idea | no external link or Wikipedia reference |
| Mutual recognition of GMP inspections for cell, gene and radiopharmaceutical plants | idea | no external link or Wikipedia reference |
| Myriam Chalabi | person | no external link or Wikipedia reference |
| Myung-Ju Ahn | person | no external link or Wikipedia reference |
| Nancy U. Lin | person | no external link or Wikipedia reference |
| Natasha B. Leighl | person | no external link or Wikipedia reference |
| Nathan A. Pennell | person | no external link or Wikipedia reference |
| Nathan Cherny | person | no external link or Wikipedia reference |
| Neeraj Agarwal | person | no external link or Wikipedia reference |
| Nemtabrutinib | drug | no external link or Wikipedia reference |
| Neoadjuvant ADC + IO replacing anthracycline chemotherapy in TNBC | idea | no external link or Wikipedia reference |
| Neoadjuvant checkpoint inhibitor → surgery (or no surgery) in dMMR colorectal cancer | pairing | no external link or Wikipedia reference |
| Neoadjuvant immunotherapy → response-adapted adjuvant | pairing | no external link or Wikipedia reference |
| Neoadjuvant immunotherapy with surgical window for glioblastoma | idea | no external link or Wikipedia reference |
| New diabetes after 50 plus weight loss triggers a pancreatic cancer check | idea | no external link or Wikipedia reference |
| New short-read sequencing platforms | technology | no external link or Wikipedia reference |
| Nicholas James | person | no external link or Wikipedia reference |
| Nicholas Turner | person | no external link or Wikipedia reference |
| Nina Bhardwaj | person | no external link or Wikipedia reference |
| Nirali N. Shah | person | no external link or Wikipedia reference |
| No accelerated approval for a combination without proof each part contributes | idea | no external link or Wikipedia reference |
| No new trial approval until the sponsor has reported its old ones | idea | no external link or Wikipedia reference |
| Noboru Yamamoto | person | no external link or Wikipedia reference |
| Nogapendekin alfa inbakicept | drug | no external link or Wikipedia reference |
| Non-endoscopic screening for Barrett's oesophagus and early adenocarcinoma | idea | no external link or Wikipedia reference |
| Non-muscle-invasive vs muscle-invasive bladder cancer (NMIBC / MIBC) | term | no external link or Wikipedia reference |
| Non-profit, open-licence lentiviral vectors and producer cell lines for CAR-T | idea | no external link or Wikipedia reference |
| Non-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route | idea | no external link or Wikipedia reference |
| Nuclear medicine and total-body PET hardware | technology | no external link or Wikipedia reference |
| Nurse-led chemotherapy day units with a doctor on a screen | idea | no external link or Wikipedia reference |
| Nurse-led follow-up clinics for survivors, freeing oncologists for active treatment | idea | no external link or Wikipedia reference |
| Obecabtagene autoleucel | drug | no external link or Wikipedia reference |
| Obi L. Griffith | person | no external link or Wikipedia reference |
| Odronextamab | drug | no external link or Wikipedia reference |
| Off-the-shelf cancer vaccines | technology | no external link or Wikipedia reference |
| Off-the-shelf KRAS vaccines after pancreatic cancer surgery | idea | no external link or Wikipedia reference |
| Off-the-shelf natural killer cells to sweep up residual disease | idea | no external link or Wikipedia reference |
| Offer HPV vaccination to women when they come for cervical screening or treatment | idea | no external link or Wikipedia reference |
| Offer the blood test for bowel cancer only to people who refuse stool tests or colonoscopy | idea | no external link or Wikipedia reference |
| Oligoprogression | term | no external link or Wikipedia reference |
| Olivier Delattre | person | no external link or Wikipedia reference |
| Oncology EHR and real-world data platforms | technology | no external link or Wikipedia reference |
| Oncology EHR modules and treatment pathways | technology | no external link or Wikipedia reference |
| Oncology hospital-at-home with remote monitoring for toxicity | idea | no external link or Wikipedia reference |
| Oncology pharmacists as protocol prescribers for supportive care and dose adjustments | idea | no external link or Wikipedia reference |
| Oncology pharmacy automation and compounding robots | technology | no external link or Wikipedia reference |
| Oncology teams order germline tests; tele-genetic counsellors handle the results | idea | no external link or Wikipedia reference |
| Oncolytic virus + PD-1 blockade | pairing | no external link or Wikipedia reference |
| Oncolytic viruses that make interleukin-12 only inside the tumour | idea | no external link or Wikipedia reference |
| One CAR-T infusion instead of autologous transplant | idea | no external link or Wikipedia reference |
| One clinical trial application accepted by regulators in every major region | idea | no external link or Wikipedia reference |
| One definitive ketogenic diet trial in glioblastoma, then stop | idea | no external link or Wikipedia reference |
| One digital PD-L1 scale that maps across all the competing assays | idea | no external link or Wikipedia reference |
| One global paediatric cancer development plan instead of separate FDA and EMA plans | idea | no external link or Wikipedia reference |
| One global rare cancer network with n-of-1 and Bayesian trial frameworks | idea | no external link or Wikipedia reference |
| One international registry, not one per country, for conditional approvals | idea | no external link or Wikipedia reference |
| One master trial for cancer prevention drugs across many precancers | idea | no external link or Wikipedia reference |
| One medical physicist covering many radiotherapy machines through remote quality assurance | idea | no external link or Wikipedia reference |
| One open atlas of how tumours escape every drug | idea | no external link or Wikipedia reference |
| One outcome record for every donated or discounted cancer drug pack | idea | no external link or Wikipedia reference |
| One standing umbrella trial for all rare cancers in a country | idea | no external link or Wikipedia reference |
| One-stop breast clinics: imaging, biopsy and a preliminary answer in a single visit | idea | no external link or Wikipedia reference |
| One-two punch: clear senescent cells after chemotherapy | idea | no external link or Wikipedia reference |
| Open licences for publicly funded cancer guidelines | idea | no external link or Wikipedia reference |
| Open the barrier so engineered immune cells can enter the brain | idea | no external link or Wikipedia reference |
| Open-source dossier-building software for academic sponsors and generic makers | idea | no external link or Wikipedia reference |
| Open-source drug discovery to clinical proof of concept for neglected cancers | idea | no external link or Wikipedia reference |
| Open, benchmarked algorithms for lines of therapy and progression from routine data | idea | no external link or Wikipedia reference |
| Oral SERD | term | no external link or Wikipedia reference |
| Oral SERD + CDK4/6 inhibitor after ESR1 emergence | pairing | no external link or Wikipedia reference |
| Organ preservation as the default after complete response in oesophageal cancer | idea | no external link or Wikipedia reference |
| Outcome-based annuity payments for potentially curative one-time therapies | idea | no external link or Wikipedia reference |
| Ovarian function suppression (OFS) | term | no external link or Wikipedia reference |
| Owen N. Witte | person | no external link or Wikipedia reference |
| Padmanee Sharma | person | no external link or Wikipedia reference |
| Paid community advisory boards with power to change protocol burden | idea | no external link or Wikipedia reference |
| Paid independent statistical review for preclinical papers that inform trials | idea | no external link or Wikipedia reference |
| Paid survivor peer-navigators as a recognised health workforce role | idea | no external link or Wikipedia reference |
| Palliative care from diagnosis for every advanced cancer, including opioid access, worldwide | idea | no external link or Wikipedia reference |
| PAM50 / intrinsic subtypes | term | no external link or Wikipedia reference |
| Pamela S. Ohashi | person | no external link or Wikipedia reference |
| Pankaj Chaturvedi | person | no external link or Wikipedia reference |
| Paolo Veronesi | person | no external link or Wikipedia reference |
| Parallel real-world cohorts for sicker patients alongside every pivotal trial | idea | no external link or Wikipedia reference |
| PARP inhibitor + AR pathway inhibitor (prostate) | pairing | no external link or Wikipedia reference |
| PARP inhibitor + bevacizumab maintenance (HRD-positive) | pairing | no external link or Wikipedia reference |
| PARP PET | technology | no external link or Wikipedia reference |
| Partha Basu | person | no external link or Wikipedia reference |
| Pasi A. Jänne | person | no external link or Wikipedia reference |
| Pasritamig | drug | no external link or Wikipedia reference |
| Patent term extension scaled to proven survival gain | idea | no external link or Wikipedia reference |
| Pathologist assistants plus AI triage to multiply pathologist capacity | idea | no external link or Wikipedia reference |
| Pathologists order genomic profiling automatically at diagnosis of advanced cancer | idea | no external link or Wikipedia reference |
| Pathology & radiology foundation models | technology | no external link or Wikipedia reference |
| Paths to cures: interception, eradication, control | roadmap | no external link or Wikipedia reference |
| Patient-derived organoids to pick ADC payloads | idea | no external link or Wikipedia reference |
| Patient-level multimodal foundation models for treatment selection | idea | no external link or Wikipedia reference |
| Patients are told which trials they qualify for at every treatment decision, in writing | idea | no external link or Wikipedia reference |
| Patients told which AI is used in their care, in plain language | idea | no external link or Wikipedia reference |
| Patrick Hwu | person | no external link or Wikipedia reference |
| Patrick M. Forde | person | no external link or Wikipedia reference |
| Patritumab deruxtecan | drug | no external link or Wikipedia reference |
| Paul G. Richardson | person | no external link or Wikipedia reference |
| Paul Nurse | person | no external link or Wikipedia reference |
| Paul Workman | person | no external link or Wikipedia reference |
| Paulo Hoff | person | no external link or Wikipedia reference |
| Pause a failed drug so the tumour becomes sensitive to it again | idea | no external link or Wikipedia reference |
| Pawel Kalinski | person | no external link or Wikipedia reference |
| Pay a different price for the same cancer drug depending on the indication | idea | no external link or Wikipedia reference |
| Pay for cancer AI only when it has outcome evidence, then pay properly | idea | no external link or Wikipedia reference |
| Pay for new biomarker tests only while evidence of clinical utility is being collected | idea | no external link or Wikipedia reference |
| Pay for one-time curative therapies as an annuity that stops at relapse | idea | no external link or Wikipedia reference |
| Pay for residual disease tests only inside a trial or registry | idea | no external link or Wikipedia reference |
| Pay for supervised exercise the way we pay for drugs | idea | no external link or Wikipedia reference |
| Pay insurers and health systems for cancers prevented and caught early | idea | no external link or Wikipedia reference |
| Pay oncologists for the time it takes to enrol a patient | idea | no external link or Wikipedia reference |
| Pay per course of radiotherapy, not per session, so short courses are not penalised | idea | no external link or Wikipedia reference |
| Pay-for-cure contracts: instalment payments for curative therapies contingent on durable remission | idea | no external link or Wikipedia reference |
| Payer-funded trials that omit surgery or radiotherapy in low-risk patients | idea | no external link or Wikipedia reference |
| Payers cover off-label combinations only inside registry-randomised trials | idea | no external link or Wikipedia reference |
| Payers pre-commit to cover off-label generics when a definitive trial is positive | idea | no external link or Wikipedia reference |
| Payers price drugs on quality-adjusted benefit, so toxicity costs the manufacturer | idea | no external link or Wikipedia reference |
| Payload-class switching as the rule for ADC sequencing | idea | no external link or Wikipedia reference |
| Payload-linker synthesis (high-potency API) | technology | no external link or Wikipedia reference |
| PD-1 blockade + AVD chemotherapy | pairing | no external link or Wikipedia reference |
| PD-1 blockade + chemoradiation (locally advanced cervical cancer) | pairing | no external link or Wikipedia reference |
| PD-1 blockade + chemotherapy in PD-L1-low NSCLC | pairing | no external link or Wikipedia reference |
| PD-1 blockade + VEGF inhibition | pairing | no external link or Wikipedia reference |
| PD-1 failure → TIL therapy | pairing | no external link or Wikipedia reference |
| PDAC organoid pharmacotyping | technology | no external link or Wikipedia reference |
| Per Hall | person | no external link or Wikipedia reference |
| Perioperative beta-blocker plus COX-2 inhibitor to reduce metastasis after surgery | idea | no external link or Wikipedia reference |
| Peritoneal metastasis | term | no external link or Wikipedia reference |
| Peritoneal-directed therapy for gastric cancer | idea | no external link or Wikipedia reference |
| Personalised cancer vaccines at commodity cost through fully automated manufacturing | idea | no external link or Wikipedia reference |
| Personalised neoantigen vaccine + PD-1 blockade | pairing | no external link or Wikipedia reference |
| Personalised stool-test cut-offs by age, sex and prior results | idea | no external link or Wikipedia reference |
| Personalised vaccines given only when the blood test turns positive | idea | no external link or Wikipedia reference |
| PET tracer manufacturing and distribution | technology | no external link or Wikipedia reference |
| PET-adapted (response-adapted) therapy | technology | no external link or Wikipedia reference |
| Peter Bartenstein | person | no external link or Wikipedia reference |
| Peter J. O'Dwyer | person | no external link or Wikipedia reference |
| Peter W. T. Pisters | person | no external link or Wikipedia reference |
| Ph-positive ALL | term | no external link or Wikipedia reference |
| Pharmacist interaction check before every oral cancer-drug prescription | idea | no external link or Wikipedia reference |
| Philip D. Greenberg | person | no external link or Wikipedia reference |
| Photobiomodulation and a taste and swallowing programme for mouth and throat toxicity | idea | no external link or Wikipedia reference |
| Photoimmunotherapy as an in situ vaccine with PD-1 blockade | idea | no external link or Wikipedia reference |
| PI3K/AKT-pathway inhibitor + endocrine therapy (± CDK4/6) | pairing | no external link or Wikipedia reference |
| Pick the radiation dose that switches the immune alarm on, not off | idea | no external link or Wikipedia reference |
| Pier Giuseppe Pelicci | person | no external link or Wikipedia reference |
| Pilar Garrido | person | no external link or Wikipedia reference |
| Pivotal trials include sites in Africa, South Asia and Latin America, sponsor-funded | idea | no external link or Wikipedia reference |
| Plan the second CAR-T target before the first one is lost | idea | no external link or Wikipedia reference |
| Plasmid DNA and mRNA raw-material manufacturing | technology | no external link or Wikipedia reference |
| Platinum chemotherapy in HRD tumours | pairing | no external link or Wikipedia reference |
| Point-of-care and decentralised cell manufacturing | technology | no external link or Wikipedia reference |
| Point-of-care randomisation built into the oncology record | idea | no external link or Wikipedia reference |
| Pool every immunotherapy trial's biomarker data into one commons | idea | no external link or Wikipedia reference |
| Population germline screening for hereditary cancer genes with cascade testing | idea | no external link or Wikipedia reference |
| Post every woman an HPV self-test kit instead of asking her to book a smear | idea | no external link or Wikipedia reference |
| Post-marketing safety monitoring stratified by ancestry and sex, with label updates | idea | no external link or Wikipedia reference |
| Pragmatic trials in patients over 75 with function, not just survival, as the primary endpoint | idea | no external link or Wikipedia reference |
| Pre-agreed update rules so an MCED test is not obsolete when its trial reads out | idea | no external link or Wikipedia reference |
| Pre-analytics: blood-collection tubes and tissue fixation | technology | no external link or Wikipedia reference |
| Pre-consented cohorts that can be randomised to future trials (TwiCs) | idea | no external link or Wikipedia reference |
| Pre-register biomarker validation studies the way trials are registered | idea | no external link or Wikipedia reference |
| Pre-registered, publicly scored AI ranking of repurposing candidates for cancer | idea | no external link or Wikipedia reference |
| Pre-specified crossover-adjusted survival in every trial that allows crossover | idea | no external link or Wikipedia reference |
| Predict immune side-effects before they happen and pre-empt them | idea | no external link or Wikipedia reference |
| Prevention & Risk | section | no external link or Wikipedia reference |
| Prevention trials aimed only at brain metastasis | idea | no external link or Wikipedia reference |
| Primo N. Lara Jr. | person | no external link or Wikipedia reference |
| Privacy-preserving linkage tokens for every cancer data holder | idea | no external link or Wikipedia reference |
| Priyanka Sharma | person | no external link or Wikipedia reference |
| Prizes for unpatentable surgical and radiotherapy techniques proven in trials | idea | no external link or Wikipedia reference |
| PRMT5/MAT2A synthetic lethality for MTAP-deleted mesothelioma | idea | no external link or Wikipedia reference |
| Prospective arm-volume surveillance to catch and reverse lymphoedema early | idea | no external link or Wikipedia reference |
| Prostate active surveillance without scheduled biopsies: MRI and blood tests decide | idea | no external link or Wikipedia reference |
| Protect hearing from cisplatin in adults as we now do in children | idea | no external link or Wikipedia reference |
| Protect the gut flora of patients about to start immunotherapy | idea | no external link or Wikipedia reference |
| Proteomics instruments and affinity platforms | technology | no external link or Wikipedia reference |
| Provisional prices for surrogate-endpoint approvals, reset when survival data arrive | idea | no external link or Wikipedia reference |
| PSA50 / PSA90 response | term | no external link or Wikipedia reference |
| PSMA PET → PSMA radioligand therapy | pairing | no external link or Wikipedia reference |
| PSMA-PET-guided metastasis-directed therapy as a curative strategy in oligorecurrent prostate cancer | idea | no external link or Wikipedia reference |
| Public cell-therapy foundries at cancer centres for academics and start-ups | idea | no external link or Wikipedia reference |
| Public data-quality scorecards for every cancer centre | idea | no external link or Wikipedia reference |
| Public payers cover academic CAR-T at cost as a benchmark for commercial prices | idea | no external link or Wikipedia reference |
| Public post-mortem reports when a cancer drug programme is stopped | idea | no external link or Wikipedia reference |
| Public procurement clauses banning data export fees and lock-in | idea | no external link or Wikipedia reference |
| Public reference standards and potency assays for CAR-T so every lab measures alike | idea | no external link or Wikipedia reference |
| Public-sector CAR-T manufacturing in India, Brazil and South Africa under $50,000 | idea | no external link or Wikipedia reference |
| Publicly funded cancer AI must release open weights and model cards | idea | no external link or Wikipedia reference |
| Publicly funded trials of lower and less frequent doses of expensive cancer drugs | idea | no external link or Wikipedia reference |
| Publish every complete response letter and negative opinion across all regulators | idea | no external link or Wikipedia reference |
| Publish the disagreement between trial doctors and independent reviewers for every trial | idea | no external link or Wikipedia reference |
| Publish why patients were screened out of each trial | idea | no external link or Wikipedia reference |
| Push residual disease detection a hundredfold deeper with whole-genome methods | idea | no external link or Wikipedia reference |
| Put cytisine, a cheap plant-based quit-smoking pill, on every essential medicines list | idea | no external link or Wikipedia reference |
| Puxitatug samrotecan | drug | no external link or Wikipedia reference |
| Pyrotinib | drug | no external link or Wikipedia reference |
| Qualify one iPSC master cell bank once for many off-the-shelf cell products | idea | no external link or Wikipedia reference |
| Quality-adjusted survival reported in every trial publication and label | idea | no external link or Wikipedia reference |
| Quantitative patient preference studies set the benefit-risk bar before phase 3 | idea | no external link or Wikipedia reference |
| Question prompt lists sent to patients before every major consultation | idea | no external link or Wikipedia reference |
| Rachel E. Rau | person | no external link or Wikipedia reference |
| Radiation Therapy | section | no external link or Wikipedia reference |
| Radical oncology: what could change the war by 2035 | roadmap | no external link or Wikipedia reference |
| Radioiodine-refractory (RAI-R) thyroid cancer | term | no external link or Wikipedia reference |
| Radionuclide generators and cold kits | technology | no external link or Wikipedia reference |
| Radiopharmaceutical roadmap: iodine → lutetium → actinium | roadmap | no external link or Wikipedia reference |
| Radiopharmaceuticals & Theranostics | section | no external link or Wikipedia reference |
| Radiopharmacy and cyclotron networks | technology | no external link or Wikipedia reference |
| Radiotherapy + immunotherapy | pairing | no external link or Wikipedia reference |
| Radiotherapy treatment planning and QA software | technology | no external link or Wikipedia reference |
| Rafael Kaliks | person | no external link or Wikipedia reference |
| Raffit Hassan | person | no external link or Wikipedia reference |
| Rahul Aggarwal | person | no external link or Wikipedia reference |
| Rajendra Badwe | person | no external link or Wikipedia reference |
| Raludotatug deruxtecan | drug | no external link or Wikipedia reference |
| Ramaswamy Govindan | person | no external link or Wikipedia reference |
| Ramon E. Parsons | person | no external link or Wikipedia reference |
| Random audits of published, funded research, like tax audits | idea | no external link or Wikipedia reference |
| Randomise a cheap antihistamine alongside immunotherapy | idea | no external link or Wikipedia reference |
| Randomise inside the registry that already follows every patient | idea | no external link or Wikipedia reference |
| Randomise the next line of treatment before the first one fails | idea | no external link or Wikipedia reference |
| Randomised trials of how to spread proven cancer treatments, not just what works | idea | no external link or Wikipedia reference |
| Randomised trials of stopping immunotherapy after one year versus continuing | idea | no external link or Wikipedia reference |
| Randomised trials to test whether biomarker-negative patients really do not benefit | idea | no external link or Wikipedia reference |
| Rapid diagnostic centres for people with vague but worrying symptoms | idea | no external link or Wikipedia reference |
| RAS(ON) inhibitors to convert unresectable pancreatic cancer to resectable | idea | no external link or Wikipedia reference |
| Re-map the tumour's surface proteins before choosing the next antibody drug | idea | no external link or Wikipedia reference |
| Re-test the metastasis, not the old primary, before every change of treatment | idea | no external link or Wikipedia reference |
| Read muscle loss automatically from scans patients already have | idea | no external link or Wikipedia reference |
| Read the spinal fluid to track brain tumours without opening the skull | idea | no external link or Wikipedia reference |
| Real-time guideline-concordance feedback for every cancer centre | idea | no external link or Wikipedia reference |
| Real-time margin assessment and image-guided surgery as the global standard | idea | no external link or Wikipedia reference |
| Reassess cancer drug prices at three years using real-world outcomes | idea | no external link or Wikipedia reference |
| Reciprocal recognition of tumour-agnostic and rare-indication approvals across regulators | idea | no external link or Wikipedia reference |
| Record and publish the symptom-to-diagnosis interval for every cancer, by hospital | idea | no external link or Wikipedia reference |
| Record how long tissue waited before fixation in every pathology report | idea | no external link or Wikipedia reference |
| Record what happens when doctors use cancer drugs off-label | idea | no external link or Wikipedia reference |
| Recorded, AI-summarised consultations given to patients by default | idea | no external link or Wikipedia reference |
| Red-team programmes that attack cancer AI before patients do | idea | no external link or Wikipedia reference |
| Reduce the dose once the cancer responds: response-adapted de-escalation trials | idea | no external link or Wikipedia reference |
| Reference laboratories and companion-diagnostic testing | technology | no external link or Wikipedia reference |
| Reference materials and open proficiency testing for residual disease tests | idea | no external link or Wikipedia reference |
| Regional cyclotron hubs for actinium-225 with an agreed actinium-227 impurity limit | idea | no external link or Wikipedia reference |
| Regional radiopharmacy hubs and harmonised transport rules for short-lived isotopes | idea | no external link or Wikipedia reference |
| Regional training hubs that produce oncologists, physicists and radiographers in-region | idea | no external link or Wikipedia reference |
| Regionally delivered mesothelin CAR-T with PD-1 blockade | idea | no external link or Wikipedia reference |
| Registry-based randomised MCED trial: a million people, no study visits | idea | no external link or Wikipedia reference |
| Registry-based randomised trials for oncology comparative effectiveness | idea | no external link or Wikipedia reference |
| Registry-embedded randomisation of treatment order in routine care | idea | no external link or Wikipedia reference |
| Regulators accept shrinking of precancer as the endpoint for prevention drug approval | idea | no external link or Wikipedia reference |
| Regulators recognise each other's companion diagnostic approvals | idea | no external link or Wikipedia reference |
| Reinhard Büttner | person | no external link or Wikipedia reference |
| Relacorilant | drug | no external link or Wikipedia reference |
| Remote consent and tele-screening so the first trial visit is a video call | idea | no external link or Wikipedia reference |
| Remove blanket exclusions for mental illness and dementia; support consent instead | idea | no external link or Wikipedia reference |
| Remove the fallopian tubes during any pelvic surgery once childbearing is finished | idea | no external link or Wikipedia reference |
| René Bernards | person | no external link or Wikipedia reference |
| Renier J. Brentjens | person | no external link or Wikipedia reference |
| Replace six-monthly ultrasound with a blood test for liver cancer in cirrhosis | idea | no external link or Wikipedia reference |
| Report time toxicity, the days a treatment consumes, in every trial and decision aid | idea | no external link or Wikipedia reference |
| Report time toxicity, the days spent in healthcare, as a standard outcome for older patients | idea | no external link or Wikipedia reference |
| Reprogramme suppressive macrophages instead of trying to delete them | idea | no external link or Wikipedia reference |
| Reprogramme the liver's own immune cells to refuse metastases | idea | no external link or Wikipedia reference |
| Require a randomised phase 2 before any phase 3 | idea | no external link or Wikipedia reference |
| Require every oncology candidate to publish how much reaches the brain | idea | no external link or Wikipedia reference |
| Require genetic and target-trial evidence before funding any repurposing phase 3 | idea | no external link or Wikipedia reference |
| Require head-to-head trials against the best in class for later entrants | idea | no external link or Wikipedia reference |
| Require post-approval evidence in patients over 75 and update labels accordingly | idea | no external link or Wikipedia reference |
| Require stage-shift or interval-cancer endpoints for AI in cancer screening | idea | no external link or Wikipedia reference |
| Rescue the biological samples from failed trials for biomarker research | idea | no external link or Wikipedia reference |
| Residual cancer burden (RCB) | term | no external link or Wikipedia reference |
| Restore weight-based dosing and vial sharing for immunotherapy in the label | idea | no external link or Wikipedia reference |
| Retention packages so trained oncology staff stay: bonds, top-ups, working equipment | idea | no external link or Wikipedia reference |
| Retire the 3+3: model-based dose finding that counts late and chronic side effects | idea | no external link or Wikipedia reference |
| Rinatabart sesutecan | drug | no external link or Wikipedia reference |
| Rindopepimut | drug | no external link or Wikipedia reference |
| Risk-stratified follow-up: low-risk survivors to primary care with fast re-entry | idea | no external link or Wikipedia reference |
| Risk-stratified lifelong care for tens of millions of survivors, automated and shared with primary care | idea | no external link or Wikipedia reference |
| Robert A. Fenstermaker | person | no external link or Wikipedia reference |
| Robert A. Gatenby | person | no external link or Wikipedia reference |
| Robert D. Schreiber | person | no external link or Wikipedia reference |
| Robert H. Mach | person | no external link or Wikipedia reference |
| Robert H. Vonderheide | person | no external link or Wikipedia reference |
| Robert Sandler | person | no external link or Wikipedia reference |
| Robert W. Stone | person | no external link or Wikipedia reference |
| Roberto Orecchia | person | no external link or Wikipedia reference |
| Robin T. Zon | person | no external link or Wikipedia reference |
| Robot-placed catheters and live imaging for drug infusion into brain tumours | idea | no external link or Wikipedia reference |
| Roger Stupp | person | no external link or Wikipedia reference |
| Rolf Kiessling | person | no external link or Wikipedia reference |
| Roll out AI-supported mammography nationally as a stepped-wedge trial | idea | no external link or Wikipedia reference |
| Roman Thomas | person | no external link or Wikipedia reference |
| Ronald Levy | person | no external link or Wikipedia reference |
| Ross L. Levine | person | no external link or Wikipedia reference |
| Rotate between drugs on a fixed schedule instead of waiting for failure | idea | no external link or Wikipedia reference |
| Round-the-clock remote treatment-planning hubs for clinics without physicists | idea | no external link or Wikipedia reference |
| Rui-Hua Xu | person | no external link or Wikipedia reference |
| Rules for retiring cancer AI when performance drops or the standard of care moves | idea | no external link or Wikipedia reference |
| Run the mouse or organoid trial at the same time as the human trial | idea | no external link or Wikipedia reference |
| Ruth Plummer | person | no external link or Wikipedia reference |
| Ryan B. Corcoran | person | no external link or Wikipedia reference |
| Ryan J. Sullivan | person | no external link or Wikipedia reference |
| S. Vincent Rajkumar | person | no external link or Wikipedia reference |
| Saad Z. Usmani | person | no external link or Wikipedia reference |
| Sabine Linn | person | no external link or Wikipedia reference |
| Sang Joon Shin | person | no external link or Wikipedia reference |
| Sara A. Hurvitz | person | no external link or Wikipedia reference |
| Sara López-Tarruella | person | no external link or Wikipedia reference |
| Sara M. Tolaney | person | no external link or Wikipedia reference |
| Sarah-Jane Dawson | person | no external link or Wikipedia reference |
| Sarcomatoid differentiation (RCC) | term | no external link or Wikipedia reference |
| Satricabtagene autoleucel | drug | no external link or Wikipedia reference |
| Scoop protection and co-publication norms to reduce academic secrecy | idea | no external link or Wikipedia reference |
| Score every model system on how well it predicted real trial results | idea | no external link or Wikipedia reference |
| Score every preclinical model by how often it predicted the clinical result | idea | no external link or Wikipedia reference |
| Screen every cancer patient for financial toxicity as a vital sign, with navigation | idea | no external link or Wikipedia reference |
| Screen every patient for financial hardship at diagnosis and connect them to help | idea | no external link or Wikipedia reference |
| Screen every patient for financial toxicity at diagnosis and refer like any other symptom | idea | no external link or Wikipedia reference |
| Screen glue-like compounds against every cancer cell line and publish it | idea | no external link or Wikipedia reference |
| Se-Hoon Lee | person | no external link or Wikipedia reference |
| Seamless phase 2/3 with pre-registered go rules as the default for new agents | idea | no external link or Wikipedia reference |
| Select patients for cell therapy by whether their tumour holds reactive T cells | idea | no external link or Wikipedia reference |
| Self-driving laboratories that run the cancer biology hypothesis loop autonomously | idea | no external link or Wikipedia reference |
| Selwyn M. Vickers | person | no external link or Wikipedia reference |
| Semir Beyaz | person | no external link or Wikipedia reference |
| Send screening invitations with a pre-booked time, not a request to call | idea | no external link or Wikipedia reference |
| Seock-Ah Im | person | no external link or Wikipedia reference |
| Sequence folate-receptor ADCs by payload class | idea | no external link or Wikipedia reference |
| Sequence: targeted therapy before immunotherapy in driver-positive NSCLC | pairing | no external link or Wikipedia reference |
| Sequencing DLL3 engager and B7-H3 ADC in relapsed SCLC | pairing | no external link or Wikipedia reference |
| Sequencing HER2 ADCs by payload after T-DXd | idea | no external link or Wikipedia reference |
| Sequential multiple-assignment randomised trials to find the best order of ADCs | idea | no external link or Wikipedia reference |
| Sergio Roman-Roman | person | no external link or Wikipedia reference |
| Serplulimab | drug | no external link or Wikipedia reference |
| Set trial enrolment targets from who actually gets the disease, and publish progress live | idea | no external link or Wikipedia reference |
| Sexual health assessed and treated as a standard toxicity domain | idea | no external link or Wikipedia reference |
| Shahneen Sandhu | person | no external link or Wikipedia reference |
| Shaji K. Kumar | person | no external link or Wikipedia reference |
| Shaoli Song | person | no external link or Wikipedia reference |
| Shaomeng Wang | person | no external link or Wikipedia reference |
| Shared splice-derived neoantigens as off-the-shelf vaccine targets | idea | no external link or Wikipedia reference |
| Shari Pilon-Thomas | person | no external link or Wikipedia reference |
| Sharon Belvin | person | no external link or Wikipedia reference |
| Sherene Loi | person | no external link or Wikipedia reference |
| Shield | drug | no external link or Wikipedia reference |
| Shilpa Gupta | person | no external link or Wikipedia reference |
| Shinji Ohno | person | no external link or Wikipedia reference |
| Shorter exclusivity for later-in-class drugs without added benefit | idea | no external link or Wikipedia reference |
| Shorter venetoclax courses in unfit AML | idea | no external link or Wikipedia reference |
| Shun Lu | person | no external link or Wikipedia reference |
| Shunji Takahashi | person | no external link or Wikipedia reference |
| Sibylle Loibl | person | no external link or Wikipedia reference |
| Sidedness (left vs right colon) | term | no external link or Wikipedia reference |
| Signatera | drug | no external link or Wikipedia reference |
| Simulate each hospital's cancer pathway as a queue to find and remove the waits | idea | no external link or Wikipedia reference |
| Single-dose HPV vaccination plus HPV self-sampling to reach WHO elimination in low-income countries | idea | no external link or Wikipedia reference |
| Single-fraction radiotherapy as the default for painful bone metastases | idea | no external link or Wikipedia reference |
| Slow the tumour's mutation engine with APOBEC inhibitors during targeted therapy | idea | no external link or Wikipedia reference |
| Small grants that pay scientists to write up abandoned projects | idea | no external link or Wikipedia reference |
| Small molecules that cut the RNA message of an undruggable oncogene | idea | no external link or Wikipedia reference |
| SMART designs to test treatment strategies, not just single drugs | idea | no external link or Wikipedia reference |
| Smart scales and health records flag unexplained weight loss for a cancer check | idea | no external link or Wikipedia reference |
| SMCC (thioether, non-cleavable) | term | no external link or Wikipedia reference |
| Social impact bonds for cancer prevention, repaid from avoided treatment costs | idea | no external link or Wikipedia reference |
| Social impact bonds that fund biosimilar switching, repaid from payer savings | idea | no external link or Wikipedia reference |
| Soften the tissue that new metastases need in order to grow | idea | no external link or Wikipedia reference |
| Solange Peters | person | no external link or Wikipedia reference |
| Solar microgrids so radiotherapy, pathology and drug fridges never lose power | idea | no external link or Wikipedia reference |
| Sonesitatug vedotin | drug | no external link or Wikipedia reference |
| Sonrotoclax | drug | no external link or Wikipedia reference |
| Spatial biology instruments | technology | no external link or Wikipedia reference |
| Sponsors deposit the confirmatory trial budget in escrow at accelerated approval | idea | no external link or Wikipedia reference |
| Squamous cell carcinoma vs adenocarcinoma of the oesophagus | term | no external link or Wikipedia reference |
| SSTR antagonist radioligands to increase tumour dose | idea | no external link or Wikipedia reference |
| SSTR PET → PRRT | pairing | no external link or Wikipedia reference |
| Stage shift | term | no external link or Wikipedia reference |
| Standards for external control arms built from federated real-world data | idea | no external link or Wikipedia reference |
| Standards for spatial and multiplex tissue biomarkers before they reach the clinic | idea | no external link or Wikipedia reference |
| Standing reflex biomarker panels per tumour type, run without an oncologist's order | idea | no external link or Wikipedia reference |
| Stanley R. Riddell | person | no external link or Wikipedia reference |
| Start low and step up: individualised titration of oral cancer drugs, randomised | idea | no external link or Wikipedia reference |
| Starve MYC-driven tumours by blocking protein production machinery | idea | no external link or Wikipedia reference |
| Starve the survivors: target the energy pathway drug-tolerant cells switch to | idea | no external link or Wikipedia reference |
| Stefan Fröhling | person | no external link or Wikipedia reference |
| Stefan Pfister | person | no external link or Wikipedia reference |
| Stephen B. Baylin | person | no external link or Wikipedia reference |
| Stephen J. Forman | person | no external link or Wikipedia reference |
| Sterile fill-finish and lyophilisation | technology | no external link or Wikipedia reference |
| Steven A. Rosenberg | person | no external link or Wikipedia reference |
| Steven E. Artandi | person | no external link or Wikipedia reference |
| Steven Le Gouill | person | no external link or Wikipedia reference |
| Steven T. Rosen | person | no external link or Wikipedia reference |
| Stomach cancer serology screening for high-risk migrant communities in low-incidence countries | idea | no external link or Wikipedia reference |
| Stop biopsying small thyroid nodules and never screen the thyroid | idea | no external link or Wikipedia reference |
| Stop failing trials earlier with pre-registered aggressive futility rules | idea | no external link or Wikipedia reference |
| Stop over-excluding people who could become pregnant; study pregnancy exposure | idea | no external link or Wikipedia reference |
| Stop routine endoscopies for non-dysplastic Barrett's oesophagus | idea | no external link or Wikipedia reference |
| Stop screening by life expectancy, not birthday, with a tool in the record | idea | no external link or Wikipedia reference |
| Stop watching stable low-risk pancreatic cysts after five years | idea | no external link or Wikipedia reference |
| Strip the platelet coat off travelling tumour cells in ctDNA-positive patients | idea | no external link or Wikipedia reference |
| Structural biology infrastructure (cryo-EM, synchrotrons, AlphaFold) | technology | no external link or Wikipedia reference |
| Structured exercise prescribed like a drug in all curative-intent cancer care | idea | no external link or Wikipedia reference |
| Structured mentorship so district general surgeons perform common cancer operations safely | idea | no external link or Wikipedia reference |
| Structured, coded radiology reports for cancer response instead of free text | idea | no external link or Wikipedia reference |
| Subscribable alerts when the standard of care changes for a patient's situation | idea | no external link or Wikipedia reference |
| Subscription pricing for checkpoint inhibitors: fixed national fee, unlimited use | idea | no external link or Wikipedia reference |
| Subtype-directed therapy for SCLC (ASCL1 / NEUROD1 / POU2F3 / inflamed) | idea | no external link or Wikipedia reference |
| Sudeep Gupta | person | no external link or Wikipedia reference |
| Sulfo-SPDB (disulfide) | term | no external link or Wikipedia reference |
| Sun Young Rha | person | no external link or Wikipedia reference |
| Sundar Jagannath | person | no external link or Wikipedia reference |
| Sung-Bae Kim | person | no external link or Wikipedia reference |
| Sung-Gyu Lee | person | no external link or Wikipedia reference |
| Supportive Care & Survivorship | section | no external link or Wikipedia reference |
| Surendra Shastri | person | no external link or Wikipedia reference |
| Surgery & Interventional | section | no external link or Wikipedia reference |
| Susan L. Cohn | person | no external link or Wikipedia reference |
| Susan M. Domchek | person | no external link or Wikipedia reference |
| Suzanne L. Topalian | person | no external link or Wikipedia reference |
| Switch drugs at maximum response, not at relapse | idea | no external link or Wikipedia reference |
| Switch off an undruggable oncogene permanently with epigenetic editing | idea | no external link or Wikipedia reference |
| Systemic-first management of HER2-positive brain metastases | idea | no external link or Wikipedia reference |
| T030 (belotecan derivative) | term | no external link or Wikipedia reference |
| TACE + immunotherapy/anti-VEGF | pairing | no external link or Wikipedia reference |
| Tae Won Kim | person | no external link or Wikipedia reference |
| Tae-You Kim | person | no external link or Wikipedia reference |
| Tailored screening for second cancers in survivors with known high-risk exposures | idea | no external link or Wikipedia reference |
| Tak W. Mak | person | no external link or Wikipedia reference |
| Takashi Kohno | person | no external link or Wikipedia reference |
| Takayuki Ueno | person | no external link or Wikipedia reference |
| Takayuki Yoshino | person | no external link or Wikipedia reference |
| Take faecal transplant plus immunotherapy to a definitive trial | idea | no external link or Wikipedia reference |
| Take lung screening scanners to supermarket car parks in the poorest areas | idea | no external link or Wikipedia reference |
| Take the blood test, and give the drug, at the right time of day | idea | no external link or Wikipedia reference |
| Takeshi Sano | person | no external link or Wikipedia reference |
| Tandem autologous transplant | technology | no external link or Wikipedia reference |
| Tanios Bekaii-Saab | person | no external link or Wikipedia reference |
| Targeted Therapy | section | no external link or Wikipedia reference |
| TCR therapeutics for non-HLA-A*02 patients | idea | no external link or Wikipedia reference |
| TCR-T cell therapy | technology | no external link or Wikipedia reference |
| Telemedicine, teleoncology, and telepathology | technology | no external link or Wikipedia reference |
| Telisotuzumab vedotin | drug | no external link or Wikipedia reference |
| TERT promoter mutation | term | no external link or Wikipedia reference |
| Test a high-fibre diet as an immunotherapy adjunct | idea | no external link or Wikipedia reference |
| Test alternating drug schedules against giving both drugs at once | idea | no external link or Wikipedia reference |
| Test cancer drugs in old and unhealthy animals, not just young fit ones | idea | no external link or Wikipedia reference |
| Test drugs on freshly cut slices of the patient's own tumour | idea | no external link or Wikipedia reference |
| Test drugs on the patient's own cancer cells when there is no trial to join | idea | no external link or Wikipedia reference |
| Test every possible mutation in every cancer gene so no result is 'uncertain' | idea | no external link or Wikipedia reference |
| Test flat versus weight-based dosing of antibodies, and use dose banding to cut waste | idea | no external link or Wikipedia reference |
| Test protein and resistance training during immunotherapy | idea | no external link or Wikipedia reference |
| Test the drug in biomarker-negative patients too, so the biomarker can be validated | idea | no external link or Wikipedia reference |
| Test whether calling Gleason 6 'not cancer' changes what men choose | idea | no external link or Wikipedia reference |
| Tetrapeptide GGFG (maleimide-GGFG-aminomethyl) | term | no external link or Wikipedia reference |
| The pathology lab triggers a trial referral the day a rare cancer is diagnosed | idea | no external link or Wikipedia reference |
| Theodore S. Hong | person | no external link or Wikipedia reference |
| Theodore S. Lawrence | person | no external link or Wikipedia reference |
| Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225) | technology | no external link or Wikipedia reference |
| Thermal ablation and cryotherapy for cervical precancer | technology | no external link or Wikipedia reference |
| Thomas A. Hope | person | no external link or Wikipedia reference |
| Thomas Bachelot | person | no external link or Wikipedia reference |
| Thomas J. Lynch Jr. | person | no external link or Wikipedia reference |
| Thomas U. Marron | person | no external link or Wikipedia reference |
| Three years of indication-specific exclusivity for proving a new cancer use of an old drug | idea | no external link or Wikipedia reference |
| Thyroid nodule FNA, Bethesda cytology & molecular classifiers | technology | no external link or Wikipedia reference |
| TIL-based omission of chemotherapy in stage I TNBC | idea | no external link or Wikipedia reference |
| Tilatamig samrotecan | drug | no external link or Wikipedia reference |
| Time immunotherapy to the moment targeted drugs make tumours visible | idea | no external link or Wikipedia reference |
| Time-stamped electronic lab notebooks submitted with the paper | idea | no external link or Wikipedia reference |
| Timothy A. Chan | person | no external link or Wikipedia reference |
| Timothy J. Eberlein | person | no external link or Wikipedia reference |
| Timothy J. Ley | person | no external link or Wikipedia reference |
| Tinengotinib | drug | no external link or Wikipedia reference |
| TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line | roadmap | no external link or Wikipedia reference |
| Tobias Janowitz | person | no external link or Wikipedia reference |
| Todd R. Golub | person | no external link or Wikipedia reference |
| Tolerability as a co-primary endpoint with its own label claim | idea | no external link or Wikipedia reference |
| Ton Schumacher | person | no external link or Wikipedia reference |
| Toni K. Choueiri | person | no external link or Wikipedia reference |
| Top journals require an independent lab to reproduce key findings before publication | idea | no external link or Wikipedia reference |
| Topoisomerase-I inhibitor payloads | term | no external link or Wikipedia reference |
| Toshihiko Doi | person | no external link or Wikipedia reference |
| Total-body PET for personalised radioligand dosing | idea | no external link or Wikipedia reference |
| Toxicity-management decision support for nurses and pharmacists | idea | no external link or Wikipedia reference |
| Track clones in blood with methylation patterns instead of mutations | idea | no external link or Wikipedia reference |
| Train and fund oncology clinicians as public content creators | idea | no external link or Wikipedia reference |
| Train every oncology team in serious-illness conversations and prompt them in the record | idea | no external link or Wikipedia reference |
| Train the bone marrow to make better anti-tumour immune cells | idea | no external link or Wikipedia reference |
| Trained moderators with evidence tools in online patient communities | idea | no external link or Wikipedia reference |
| Transplant-free Ph-positive ALL for MRD-negative adults | idea | no external link or Wikipedia reference |
| Trastuzumab brengitecan | drug | no external link or Wikipedia reference |
| Trastuzumab cardiotoxicity | term | no external link or Wikipedia reference |
| Trastuzumab rezetecan | drug | no external link or Wikipedia reference |
| Treat brain metastases as a disease with its own trials programme | idea | no external link or Wikipedia reference |
| Treat cachexia as a disease: GDF-15 blockade plus anabolic and nutrition bundles | idea | no external link or Wikipedia reference |
| Treat cachexia before it starts | idea | no external link or Wikipedia reference |
| Treat immunotherapy side-effects without wiping out the response | idea | no external link or Wikipedia reference |
| Treat insomnia in survivors and measure whether the cancer notices | idea | no external link or Wikipedia reference |
| Treat resistance like an infectious disease and run national surveillance | idea | no external link or Wikipedia reference |
| Treat the body cavity, not the bloodstream, for surface spread | idea | no external link or Wikipedia reference |
| Treat the draining lymph node before removing it | idea | no external link or Wikipedia reference |
| Treat wasting like sepsis: a trigger, a bundle, an audit | idea | no external link or Wikipedia reference |
| Trevor J. Pugh | person | no external link or Wikipedia reference |
| Trial-in-a-box: a preconfigured protocol kit any hospital can open for a rare cancer | idea | no external link or Wikipedia reference |
| Trials of low-cost opioid alternatives where morphine supply is unreliable | idea | no external link or Wikipedia reference |
| Trials of structured cognitive rehabilitation for cancer-related cognitive impairment | idea | no external link or Wikipedia reference |
| TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET | roadmap | no external link or Wikipedia reference |
| TROP2 PET | technology | no external link or Wikipedia reference |
| TROP2 PET → TROP2 ADC selection | pairing | no external link or Wikipedia reference |
| TROP2 PET to choose and sequence TROP2 ADCs | idea | no external link or Wikipedia reference |
| TSH suppression | term | no external link or Wikipedia reference |
| Tubulin inhibitor payloads | term | no external link or Wikipedia reference |
| Tucatinib + trastuzumab + capecitabine for brain metastases | pairing | no external link or Wikipedia reference |
| Tumour proportion score (TPS) | term | no external link or Wikipedia reference |
| Tumour-on-a-chip with blood flow to test whether big drugs actually get in | idea | no external link or Wikipedia reference |
| Turn a brake back on: drugs that reactivate the PP2A phosphatase | idea | no external link or Wikipedia reference |
| Turn chromosomal chaos into a weakness with KIF18A inhibitors | idea | no external link or Wikipedia reference |
| Turn off the error-prone repair that manufactures resistance mutations | idea | no external link or Wikipedia reference |
| Turn one tumour into a vaccine to treat all the others | idea | no external link or Wikipedia reference |
| Turn the map of immune cells inside a tumour into a standardised test | idea | no external link or Wikipedia reference |
| Two-day CAR-T manufacture paired with rapid release tests that regulators accept | idea | no external link or Wikipedia reference |
| Two-page plain-language consent with teach-back for every cancer trial and treatment | idea | no external link or Wikipedia reference |
| Two-target antibody drugs to close the antigen escape route | idea | no external link or Wikipedia reference |
| Two-week pre-operative windows to compare combination biology head to head | idea | no external link or Wikipedia reference |
| Two-year translational fellowships that pay scientists to develop their own discovery | idea | no external link or Wikipedia reference |
| Ulceration (melanoma) | term | no external link or Wikipedia reference |
| Ulrich Keilholz | person | no external link or Wikipedia reference |
| Ultrasound restraint and surveillance to reverse thyroid cancer overdiagnosis | idea | no external link or Wikipedia reference |
| Unmask hidden antigens with a short epigenetic course before immunotherapy | idea | no external link or Wikipedia reference |
| Update hospital order sets within 30 days of a guideline change | idea | no external link or Wikipedia reference |
| Upfront reduced-dose regimens tested head-to-head in frail older patients | idea | no external link or Wikipedia reference |
| Urine tumour DNA to replace surveillance cystoscopy in NMIBC | idea | no external link or Wikipedia reference |
| Ursula A. Matulonis | person | no external link or Wikipedia reference |
| Use a blood test at six weeks to decide whether to keep going | idea | no external link or Wikipedia reference |
| Use a hypoxia scan to pick patients for adenosine-pathway drugs | idea | no external link or Wikipedia reference |
| Use a polygenic risk score to set when screening starts | idea | no external link or Wikipedia reference |
| Use antibodies to deliver protein-destroying drugs into the right cells | idea | no external link or Wikipedia reference |
| Use food effects to cut the dose and cost of oral drugs that absorb better with meals | idea | no external link or Wikipedia reference |
| Use imaging to find the window when tumour blood vessels are working properly | idea | no external link or Wikipedia reference |
| Use patient organoids to check a cell therapy will work before infusing it | idea | no external link or Wikipedia reference |
| Use pre-surgery immunotherapy windows as the field's biomarker engine | idea | no external link or Wikipedia reference |
| Use residual disease tests to decide who needs ten years of hormone therapy | idea | no external link or Wikipedia reference |
| Use SLFN11 status to decide which antibody-drug payload to give next | idea | no external link or Wikipedia reference |
| Use the brain's own transport door to carry antibody drugs across | idea | no external link or Wikipedia reference |
| Use the trend in routine blood counts, not a single threshold, to spot cancer | idea | no external link or Wikipedia reference |
| Use tumour DNA in blood to decide when to pause treatment in metastatic cancer | idea | no external link or Wikipedia reference |
| Uwe Haberkorn | person | no external link or Wikipedia reference |
| Uwe Oelfke | person | no external link or Wikipedia reference |
| Vaccinate against the resistance mutation before it takes over | idea | no external link or Wikipedia reference |
| Vaccines aimed only at mutations shared by every tumour cell | idea | no external link or Wikipedia reference |
| Val-Ala dipeptide | term | no external link or Wikipedia reference |
| Validate and reimburse AI contouring and planning to expand radiotherapy capacity | idea | no external link or Wikipedia reference |
| Validate low-cost metronomic oral regimens in phase 3 and carry them into guidelines | idea | no external link or Wikipedia reference |
| Validate real-world progression against central imaging review | idea | no external link or Wikipedia reference |
| Validate real-world progression endpoints so pragmatic trials can use them | idea | no external link or Wikipedia reference |
| Vanita Noronha | person | no external link or Wikipedia reference |
| Variant allele frequency (VAF) | term | no external link or Wikipedia reference |
| Venetoclax + hypomethylating agent | pairing | no external link or Wikipedia reference |
| Venetoclax + obinutuzumab (12 months) | pairing | no external link or Wikipedia reference |
| Vepdegestrant | drug | no external link or Wikipedia reference |
| Version control and locked reference sets for AI algorithms used as companion diagnostics | idea | no external link or Wikipedia reference |
| Video palliative care as an equivalent default option for patients far from a team | idea | no external link or Wikipedia reference |
| Vijay Patil | person | no external link or Wikipedia reference |
| Vimseltinib | drug | no external link or Wikipedia reference |
| Vincent K. Tuohy | person | no external link or Wikipedia reference |
| Vincenzo Valentini | person | no external link or Wikipedia reference |
| Viral vector manufacturing (lentiviral, retroviral, AAV) | technology | no external link or Wikipedia reference |
| Virginia Sun | person | no external link or Wikipedia reference |
| Virtual cell roadmap: from bulk omics to a predictive model of a cancer cell | roadmap | no external link or Wikipedia reference |
| Vocational rehabilitation integrated into cancer care so survivors can return to work | idea | no external link or Wikipedia reference |
| Volker Heinemann | person | no external link or Wikipedia reference |
| Volunteer-led neighbourhood palliative networks, the Kerala model, adapted elsewhere | idea | no external link or Wikipedia reference |
| Vusolimogene oderparepvec | drug | no external link or Wikipedia reference |
| Watch routine care for drug combinations that quietly make cancer treatment worse | idea | no external link or Wikipedia reference |
| Watch small kidney tumours rather than remove them, with a national registry | idea | no external link or Wikipedia reference |
| Watch the immune system's response in the blood three weeks in | idea | no external link or Wikipedia reference |
| Wearable activity data as a validated real-world endpoint | idea | no external link or Wikipedia reference |
| Weimin Li | person | no external link or Wikipedia reference |
| Weiping Zou | person | no external link or Wikipedia reference |
| Wendy Parulekar | person | no external link or Wikipedia reference |
| Wenfeng Fang | person | no external link or Wikipedia reference |
| What actually holds T cells at the tumour border? | idea | no external link or Wikipedia reference |
| What decides which disseminated cells ever colonise? | idea | no external link or Wikipedia reference |
| What makes a neoantigen actually immunogenic? | idea | no external link or Wikipedia reference |
| When the blood test is positive, hunt for the lesion with sensitive imaging | idea | no external link or Wikipedia reference |
| Which patients' blood clones will become leukaemia after treatment? | idea | no external link or Wikipedia reference |
| WHO prequalification plus pooled demand to push biosimilar prices below 10% of the originator | idea | no external link or Wikipedia reference |
| Whole-body MRI | technology | no external link or Wikipedia reference |
| Whole-body MRI plus blood DNA surveillance for people with Li-Fraumeni syndrome | idea | no external link or Wikipedia reference |
| Whole-patient digital twins validated in prospective randomised trials | idea | no external link or Wikipedia reference |
| Whole-slide scanners and image management | technology | no external link or Wikipedia reference |
| William G. Kaelin Jr. | person | no external link or Wikipedia reference |
| William G. Nelson | person | no external link or Wikipedia reference |
| Won Ki Kang | person | no external link or Wikipedia reference |
| Woong-Yang Park | person | no external link or Wikipedia reference |
| WRN inhibitors: a second synthetic-lethal win for mismatch-repair cancers | idea | no external link or Wikipedia reference |
| Xichun Hu | person | no external link or Wikipedia reference |
| Yelena Y. Janjigian | person | no external link or Wikipedia reference |
| Yeon Hee Park | person | no external link or Wikipedia reference |
| Yi-Long Wu | person | no external link or Wikipedia reference |
| Yi-Zhou Jiang | person | no external link or Wikipedia reference |
| Yoon-Koo Kang | person | no external link or Wikipedia reference |
| You Lu | person | no external link or Wikipedia reference |
| Yuankai Shi | person | no external link or Wikipedia reference |
| Yuichiro Ohe | person | no external link or Wikipedia reference |
| Yuko Kitagawa | person | no external link or Wikipedia reference |
| Yung-Jue Bang | person | no external link or Wikipedia reference |
| Yuquan Wei | person | no external link or Wikipedia reference |
| Zebrafish avatars for a drug answer within a week | idea | no external link or Wikipedia reference |
| Zelenectide pevedotin | drug | no external link or Wikipedia reference |
| Zhi-Ming Shao | person | no external link or Wikipedia reference |
| Zidesamtinib | drug | no external link or Wikipedia reference |
| Ziftomenib | drug | no external link or Wikipedia reference |
| Zilovertamab vedotin | drug | no external link or Wikipedia reference |
| Zongertinib | drug | no external link or Wikipedia reference |